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Cancer metastasis often leads to patient mortality. Recent advancements in technology 
have reinvigorated cancer research by enabling the detection of circulating tumor cells 
(CTCs) in the peripheral blood circulation, which may participate in cancer metastasis. 
Increased CTC counts in blood have been found to correlate with worsened patient 
prognosis. However, CTCs are rare events, and are phenotypically and genetically 
heterogeneous. These render isolation and subsequent characterization extremely 
challenging, and hinders the exhaustive profiling of CTCs and detection of positive blood 
samples with low cancer cell counts. Recently, the generation of CTC cell lines had been 
reported, opening new possibilities in the characterization of CTCs and screening for 
anti-cancer drugs. Though promising, these techniques have low efficiency (<20% rate in 
formation of cultures), require lengthy procedures and additional pre-enrichment 
techniques.  
 
This study presents a label-free technique using microwells for the culture of CTCs from 
patients at different stages of breast cancer. Clusters comprising of putative CTCs were 
established directly from the nucleated cell fraction after red blood cell (RBC) lysis. 
Healthy blood samples, serving as controls, led to cellular debris or a monolayer of 
residual blood cells. This protocol allowed unbiased enrichment of a wide range of 
heterogeneous cancer cells, leading to a higher detection efficiency (62.2%, n=391) in 
contrast to conventional enrichment techniques (<50%). A minimal sample input of 2.5 
ml of patient’s blood was required and results could be obtained rapidly after short-term 




Resultant multilayered clusters comprised Small putative CTCs (≤25 µm; high nuclear to 
cytoplasmic (N/C) ratio; CD45-) and larger blood cells (>25 µm; low N/C ratio; either 
macrophages (CD68+) or natural killer cells (CD56+)). Relative proportion of putative 
CTCs increased with the depletion of most leukocytes. Characterization of the cultures 
revealed cellular heterogeneity via histological staining, protein and gene expression 
analyses. Cultured CTCs presented a range of epithelial–mesenchymal transition (EMT) 
phenotypes. Among these, a subset of CTCs were identified that expressed markers 
correlating to breast cancer stem cells (CSC), another rare subpopulation of carcinoma 
cells with reported drug resistance/tolerance and stem cell-like properties. The 
combination of hypoxia and tapered microwell topography led to the highest proportion 
of CSC-like cells. Characterization with invadopodia assays suggested the presence of 
more invasive cancer cells. Intriguingly, a large proportion of cultured cells appeared to 
be arrested in G1/S phase of the cell cycle, a likely protective mechanism, but could be 
induced into spheroids upon passaging into fresh 3D matrix or non-adherent well dishes. 
 
From a clinical perspective, the ability to form clusters correlated with patient overall 
survival (OS), and was reduced in samples obtained at later treatment time points. A 
portion of samples from patients with early-stage cancer also lead to positive cultures, 
even a year after treatment, which may hint at an increased risk of relapse. Overall, the 
microwell CTC culture assay can potentially serve as a valuable tool for rapid monitoring 
of patient prognosis and expansion of the CTC cohort, which may enable CTC profiling 
and insights on tumor biology and metastasis. 
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Chapter 1: Introduction  
1.1 Background on cancer 
1.1.1 Cancer heterogeneity and mortality 
Cancer research has undergone tremendous boost over the past few years, spurred on by 
the validation that cancer phenotypes can be induced from both somatic and germ line 
mutations. These mutations act together to affect multiple signaling pathways, resulting in 
a vast degree of tumor heterogeneity (Stratton et al. 2009).  
 
The extent of tumor heterogeneity presents a problem during targeted therapeutics, and is 
one of the main reasons why cancer often leads to morbidity and fatality worldwide. 
According to the World Health Organization (WHO), 14 million new cancer cases were 
reported in the year 2012, and cancer-related deaths amounted to more than 8 million 
people (Stewart and Wild 2014).  
 
Another major factor contributing to cancer fatality is the lack of early intervention, 
which often results in the patient developing metastases (Chambers et al. 2002). In fact, 
most clinical cases were only detected after cells from the primary tumor had migrated to 
other parts of the body (Nguyen et al. 2009). Due to the current lack of treatment 
strategies, it is generally accepted that the core treatment objective is to achieve 
secondary prevention with the aid of more sensitive detection methods, enabling early 
intervention before further spread of disease. Hence, an advancement in technologies to 





1.1.2 Cancer metastasis 
Metastasis is a complex, multistep process (Steeg 2006, Nguyen et al. 2009) (Figure 1.1). 
These processes are mediated by stimulation from the microenvironment, as described in 
the ‘seed and soil hypothesis’ established in 1989 (Paget 1989, Talmadge and Fidler 
2010). Paget described the occurrence of metastasis as a result between the interactions of 
metastatic tumor cells (‘seed’) and its microenvironment (‘soil’), a hypothesis which has 
since been confirmed by various experimental data. Occurrence of metastasis is highly 
correlated to worsened patient prognosis.  
 
Metastasis is regulated by genetic, environmental, physical and mechanical factors 
present in the microenvironment. Although detailed mechanisms of the metastatic 
cascade remains an enigma, recent investigations are starting to map the pieces together 
(Gupta and Massague 2006).  
 
The primary tumor is established when normal epithelial cells undergo cellular aberration 
after long-term exposure to mutagens. In most cases, this leads to the formation of an 
adenoma (cells with a loss of apico-basal polarity and growth control) and subsequent 
transition to carcinoma in situ. Vascularisation occurs to supply the growing tumor with 
nutrients, a process termed as angiogenesis (Carmeliet and Jain 2011), while the tumor 
remains confined within the basement membrane. At this point of time, the tumor already 
presents genetic or physical heterogeneity, and is associated with several other cell types, 
including macrophages, white blood cells, cancer-associated fibroblasts (myofibroblasts), 
all of which are gathered in close proximity within extracellular matrix (ECM). The 
combination of all these cell types constituting the stromal niche provides various stimuli 
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for cells, triggering epithelial to mesenchymal transition (EMT) (Kalluri and Weinberg 
2009, Thiery and Lim 2013) as carcinoma cells migrate from the stromal niche 
(Barcellos-Hoff et al. 2013) to the blood vessel. This is followed by the hematogeneous 
dissemination in the bloodstream, and these dissociated cells are termed circulating tumor 
cells (CTCs). Although it is now known that these cells are technically cancer cells (not 
tumor cells, which comprise of both malignant and non-malignant cells), the term CTC 
will be preserved in the thesis to allow further reference. Metastatic carcinoma cells are 
highly deformable (Hur et al. 2011) and may extravasate as single cells or clusters 
(microemboli), the latter which are often  associated with platelets (Labelle et al. 2011). 
Carcinoma cells undergo mesenchymal to epithelial transition (MET) after arrest at a 
distant secondary site.  
 
The two major processes leading to metastasis, namely intravasation and extravasation, 
are likely to be driven by EMT and MET, as initially proposed by Thiery in 2002 (Thiery 
and Sleeman 2006, Chaffer and Weinberg 2011). These processes promote the loss or 
gain of cell-cell adhesion respectively, and may also be regulated by the expression of 





Figure 1.1 Schematic summarizing the major steps of the metastatic cascade. Normal 
epithelial cells undergo cellular aberration, forming adenoma and subsequently carcinoma 
in situ. Capillaries are formed to supply nutrients to the growing primary tumor. In the 
stromal niche, other cell types, such as macrophages, white blood cells, myofibroblast are 
also present, all of which are bundled in close proximity with the carcinoma cells by the 
extracellular matrix. The carcinoma cells undergo EMT, detach from the stromal niche 
and penetrate into the blood vessel, in a process known as intravasation. Carcinoma cells 
that enter the peripheral bloodstream are termed as CTCs, which are then disseminated 
through the body via the bloodstream. Some carcinoma cells undergo MET. Under 
suitable environmental stimuli, single or a cluster of carcinoma cells of various epithelial 
(E), mesenchyal (M) or intermediate EM phenotypes may be arrested within the 
endothelial cell lining of the blood vessel, eventually migrating into the surrounding local 
tissue (extravasation). Extravasated cells may generate micrometastasis and subsequent 
macrometastasis. Major steps are indicated in red. 
 
1.2 Circulating Tumor cells (CTCs) 
Metastasis results in the shedding of CTCs into the peripheral bloodstream. The 
metastatic cascade has been investigated mainly with the use of animal models, such as 
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the mouse (Kienast et al. 2010, Zlotnik et al. 2011), and was previously thought to occur 
only at advanced disease stages. However in recent years, technological advancements 
enabled scientists to detect CTCs in patients with early stage cancer (Nagrath et al. 2007, 
Husemann et al. 2008), implying the possible application of CTC detection in early 
cancer diagnosis.  
 
Although documented in the 1800s (Ashworth 1869), the presence of CTCs remained as a 
hypothesis till technological breakthroughs in the past decade, which allowed for the 
isolation of CTCs from patients with metastatic cancer (Allard et al. 2004, Nagrath et al. 
2007, Gascoyne et al. 2009, Stott et al. 2010, Hou et al. 2013). CTCs can now be 
routinely detected from blood samples (liquid biopsies), which is a less stressful and 
invasive procedure as compared to conventional tumor biopsies (Loeb et al. 2013). 
Preliminary studies correlate high CTC counts in blood of metastatic patients with lower 
overall survival (Cristofanilli et al. 2004, Cristofanilli et al. 2005, de Bono et al. 2008), 
rendering it as a potential indicator for prognosis. CTC counts also correlate with disease 
progression (Nole et al. 2008) and treatment efficacy (Reuben et al. 2008).  
 
Current consensus defines CTCs as nucleated cells with high nuclear to cytoplasmic (N/C) 
ratio, and which express epithelial markers (e.g. cytokeratin (CK) and Epithelial Cell 
Adhesion Molecule (EpCAM)), but not leukocyte markers (e.g. CD45). This definition 
was adopted from the standard used for disseminated tumor cell (DTC) detection in the 
1990s (Borgen et al. 1999). DTCs are cancer cells found in the bone marrow, and also 
originate from tumors.  
 
However, it is now known that this definition is inadequate for cancer cell identification. 
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Subpopulations of CTCs may undergo EMT (Thiery 2002), leading to varied phenotypes 
which could be conferred with protective traits to avoid anoikis (programmed cell death) 
(Howard et al. 2008) or senescence (Ansieau et al. 2008). Some cells may even acquire 
stem cell-like properties (Singh et al. 2003, Clevers 2011). In fact, cancer cells often exist 
as a range of either full-blown or intermediate EMT phenotypes, to provide favoring 
characteristics at each stage of the metastatic cascade (Jordan et al. 2011, Davidson et al. 
2012, Huang et al. 2013, Yu et al. 2013). 
 
The exact frequency of CTCs in blood has been under debate, partly due to the varied 
detection sensitivity and recovery efficiency present with each enrichment assay. Previous 
experiments using mouse models with highly metastatic disease estimate the amount of 
shed carcinoma cells per day to be around 10k (Fidler 1970). A later study even suggested 
this number to be a million per day for each gram of tumor (Butler and Gullino 1975). 
The frequency of CTCs also varies with disease stage and presence of treatment or 
surgical procedures that may evoke heightened release of CTCs (Fidler 1970).  
 
Exact mapping of the timeline for CTC occupancy in blood is still unknown, but vaguely 
estimated to be several hours or days. Most of these cells are believed to have brief 
periods in circulation (Riethdorf and Pantel 2009, Coumans et al. 2013). When cancer 
cells were injected into mouse, only 1% of cells were left circulating in blood after 24 hrs. 
The high loss of CTCs is mainly attributed to damage induced by the fluid shear flow or 
host immune response (Chambers et al. 2002), since single CTCs are vulnerable in the 
absence of its stromal niche. Thus, the process of metastasis is not an efficient process 
(Weiss 1990, Brodland and Zitelli 1992), and is also further impeded by the fact that only 
7 
 
few CTCs have metastatic potential.  
 
Cancer cells which remain in circulation are likely to remain viable. However, most of 
these persisting CTCs may undergo dormancy (Chambers et al. 2002, Coumans et al. 
2013). Dormant cancer cells are likely to proliferate again under the right circumstances. 
Ability of a CTC to generate micrometastases in vivo may be heightened by a myriad of 
factors, such as encounters with fenestrated blood vessels that encourage extravasation, or 
suitable microenvironmental stimuli (chemical secretions, topography and other forms of 
interactions) provided by the premetastatic niche (Nguyen et al. 2009, Barcellos-Hoff et 
al. 2013).  
 
1.2.1 Breast Cancer CTCs and statistics 
CTCs of various cancer types have now been isolated from blood of patients, including 
but not limited to, breast, prostate and lung cancer (Farace et al. 2011). Clinical trials of 
patients with breast cancer, one of the most common cancer types in women, were the 
focus in this study.  
 
There is a great necessity to improve the prospects of overall survival (OS) and 
progression free survival (PFS) in breast cancer patients, which vary due to a range of 
demographic factors such as age, tumor status, stage and grade. Patients with PFS do not 
experience deterioration in their condition during or after treatment, while the OS reflects 
the percentage of patients who survived with respect to time after treatment. According to 
the data from American Cancer Society’s Cancer Facts and Figures 2014 report, 40,000 
out of 232670 women (17.1%) diagnosed with breast cancer died from the disease. A 
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portion of treated patients also remains vulnerable to the relapse of the disease, which 
obscures recovery, both physically and mentally. Patients with postoperative recurrence 
usually have poorer prognosis, which made monitoring of disease even more critical. In 
Singapore, the estimated relapse frequency for patients with early stage breast cancers is 
10-20% for stage I, 30-40% for stage II and 50-70% for stage III cancer (Saxena et al. 
2012).  
 
The main factor for mortality of cancer patients is the presence of metastatic lesions 
(Gupta and Massague 2006). Logically, the presence of CTCs is inversely correlated to 
patient response to therapy (Farace et al. 2011), a parameter usually determined by the 
shrinkage of tumor mass (Therasse et al. 2000). CTC counts may even correspond better 
than tumor size measurement (Foulkes et al. 2009). Although a recent study did not 
achieve any correlation between CTC counts with tumor status and location (Rack et al. 
2010), CTCs may still serve as a superior method when compared to conventional means 
of evaluation (e.g. biopsy).  
 
The current methods utilized in clinical settings for tumor detection, which affect 
subsequent treatment evaluation, are highly limited by the device’s sensitivity limit, thus 
preventing observation of tumors smaller than 5 mm or the monitoring of minute changes 
in tumor size (Erten et al. 2010). In fact, a high percentage of patients initially classified 
with large operable (localized) tumors, were later found to have metastasized cancer, 
which often result in death due to the lack of prompt treatment (Coen et al. 2002, 
Riethdorf et al. 2008). Hence, the generation of novel and sensitive assays to separate 
blood components, enabling CTC enrichment, is a highly desirable approach (Vona et al. 
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2000, Loberg et al. 2004, Toner and Irimia 2005, Nagrath et al. 2007, Gascoyne et al. 
2009, Stott et al. 2010, Yu et al. 2011, Warkiani et al. 2014a). This may allow better 
prospects for the cancer patients via the prompt and accurate establishment of suitable 
clinical trials.  
 
1.2.2 Clinical significance of CTCs 
Scientists and clinicians have rekindled the ‘seed and soil’ theory (Paget 1989), and 
anticipate that CTCs will be of clinical utility (Paget 1989, Cristofanilli et al. 2004). 
Characterization of CTCs may fill many knowledge gaps in tumor biology, especially in 
the process of metastasis (Pantel and Alix-Panabieres 2007, Pantel et al. 2008). 
 
TCs can be detected in patients with early stage cancer, and CTC counts may even 
correlate better to disease status as compared to current detection methods such as X-ray 
computed tomography, or positron emission tomography (PET) scan techniques 
(Weissleder 2002). The presence of CTCs in patients with early stage cancers also 
contradicts previous notion that cancer cell dissemination only occurs late in the disease 
progression (Loberg et al. 2004, Riethdorf et al. 2008).  
 
CTCs are heterogeneous and may recapitulate the tumor phenotypes better than tumor 
biopsies. Phenotyping of enriched CTCs reveals that another subpopulation of 
tumorigenic carcinoma cells are present within the CTCs (Clevers 2011). These 
tumorigenic cells, termed as ‘cancer stem cells (CSCs)’, also originate from tumors and 
may present tolerance (Kang and Kang 2007, Eyler and Rich 2008, Sharma et al. 2010) or 
resistance (Li et al. 2008, Singh and Settleman 2010) to certain chemotherapeutic drugs. 
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These subpopulations of cancer cells with favorable traits for survival may be valuable 
drug targets for novel therapies.  
 
The extent of CTC heterogeneity is far from being understood, as seen in terms of 
morphology, proteomic or genomic profiling (Pantel and Brakenhoff 2004). Some of 
these CTCs may be conferred with favorable characteristics for propagation and survival, 
such as the expression of human epidermal growth factor receptor 2 (HER2), which 
render them more susceptible to complete the metastatic cascade. Due to this variation, 
scientists have not been able to capture a complete spectrum of CTCs to accurately 
profile and confirm their clinical utility, leading to a certain amount of controversy (Alix-
Panabieres and Pantel 2014). In fact, not all patients detected with CTCs may suffer from 
observable symptoms or progression in disease (Braun et al. 2005). Despite these findings, 
the presence of persisting CTCs correlates well with an increased risk of disease relapse 
(Pantel and Brakenhoff 2004).  
 
Models of metastasis in mice demonstrate that the majority of CTCs have short half-lives, 
a small portion of which remains viable but dormant (Chambers et al. 2002, Meng et al. 
2004). The dormancy of CTCs and the process of triggering them into proliferation are 
not well investigated, although long term studies of patients under relapse suggest that 
cancer cells may exit dormancy due to accumulation of new mutations or a change in the 
microenvironment (Aguirre-Ghiso 2007). To achieve better functional studies and clinical 
utility, novel techniques are required to detect or enrich significant proportions of CTCs, 




1.3 Current literature on CTC enrichment 
Detection of a heterogeneous cell population is a technically challenging process. Cells 
are small entities in the range of microns, and hence require equipment with a high degree 
of tunability to separate cells under precise control and selectivity (Van Vliet and Bao 
2003). Thus, devices attempting to sort cells have to operate at a micro-scale level, 
usually via microfluidics (Bhagat et al. 2010) or microelectronics (Wei et al. 2014).  
 
The miniaturization of systems allows analysis with low sample input (Bashir 2004, 
Whitesides 2006), which is favorable for handling rare samples. However, the sheer 
extent of CTC heterogeneity induces vast difficulty for its enrichment (Pantel et al. 1999). 
This is further exacerbated by their extremely low abundance (<1000 cells ml
-1
) in 
peripheral blood (Zieglschmid et al. 2005), which comprises of other billions of blood 
cells, including erythrocytes (red blood cell; RBC), leukocytes (white blood cell; WBC) 
and thrombocytes (platelets) (Anthea et al. 1993, Racila et al. 1998). Challenges and 
limitations of these techniques will be further discussed in Section 1.4. 
 
In the past decade, a surge in the fields of nanomaterials and microfluidics has led to an 
impressive number of techniques developed to separate blood and small particles. Several 
methods have been adopted for the detection and enrichment of CTCs, with notable 





Table 1.1 List of notable CTC enrichment techniques. These include methods based on antigen-recognition 
(immunophenotyping), physical characteristics (size and deformability) as well as membrane electrical or invasive properties. 













2.7 5 to 1,281  9.2% ± 0.1% 
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3D microfilter    
Filtration 
NA ND ND (Zheng et al. 2011) 
Isolation by Size of Epithelial 
Carcinoma cells  
6 1 to 4 ND (Vona et al. 2004) 
Microcavity array system  NA ND ND 
(Hosokawa et al. 
2013) 
CT biochip 5 ND 80-90% (Tan et al. 2010) 
Separable Bilayer 
Microfiltration Device 
0.1 ND ND (Zhou et al. 2014) 
Spiral inertial biochip 
Inertial focusing 
7.5   5 to 100 ~10% (Hou et al. 2013) 
Trapezoidal biochip 7.5 3 to 125 0.6-25% 
(Warkiani et al. 
2014a) 
Vortex chip 7.5 23–317 57–94 (Sollier et al. 2014)  
CTC-iChip 
Inertial focusing 
coupled with ferrofluid 
10 0.5 to 610 7.80% 
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1.3.1 Label-dependent techniques  
The first available techniques for CTC detection relied on affinity-based methods. 
CTCs can be enriched via positive selection with epithelial, tumor- or organ-
associated markers, or negative selection via the removal of blood cells (Table 1.2). 
Conventional methods utilize whole blood samples for flow cytometers (He et al. 
2007), which are straightforward but of low efficiency.  
 
Currently, CTCs are more often enriched via binding to substrates coated with 
membrane-specific epithelial antibodies. This step is usually coupled to microfluidics, 
hence enabling precise processing under controlled laminar conditions. Substrates 
utilized for this purpose include micropillars (Nagrath et al. 2007, Gleghorn et al. 
2010, Stott et al. 2010, Wang et al. 2011), microchannels (Du et al. 2007), nanotubes 
(Shao et al. 2008), nanoporous surfaces (Mittal et al. 2012), microbeads (Deng et al. 
2008), immunomagnetic beads or ferrofluid (Allan et al. 2005, Riethdorf et al. 2007). 
In these procedures, whole blood or nucleated cells after RBC removal were obtained 
from patients, followed by incubation with antibody-coated substrates and subsequent 
separation from blood cells via wash to remove unbound cells. Additional techniques, 
such as the application of a magnetic field, may be coupled with this method for a 
more precise enrichment. Other sophisticated techniques, such as the fiber optic array 
scanning technologies (Krivacic et al. 2004) or Bio-MEMS (Du et al. 2007), are also 
utilized.  
 
Methods which require cell-substrate interactions usually use EpCAM, a cell surface 
antigen (Herlyn et al. 1979) associated with stem cell proliferation (Nagao et al. 2009) 
and regulation of cyclin expression (Munz et al. 2004). Overexpression of EpCAM 
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leads to epithelial-associated phenotypes (Herlyn et al. 1979).  
 
Enrichment of other epithelial markers has been shown to exceed the sensitivity of 
assays utilizing only EpCAM. Hence, recent affinity-based CTC detection techniques 
also target other epithelial markers, messenger ribonucleic acid (mRNAs) of genes 
over-expressed in cancer cells and tumor- or organ-associated antigens (Table 1.2). To 
achieve better purity of the enriched CTC population, negative selection is sometimes 
added as a post-processing step to remove contaminating leukocytes expressing CD45 
(Allard et al. 2004, Deng et al. 2008). The techniques listed in Table 1.1, as well as 
the markers stated in Table 1.2, may be used in combination (e.g. Ikonisys, New 




Table 1.2 List of markers utilized for CTC enrichment via positive selection 
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(Kruger et al. 2001) 
 HER2-neu  (Riethdorf et al. 2010) 
 Mucin-1  (Mehes et al. 2001) 
Prostate 
 Prostate specific 
antigen (PSA)  
No 




(Stott et al. 2010) 
 
Amongst the label-dependent (affinity binding) techniques, CellSearch system 
(Veridex LLC, Raritan, NJ, USA) is currently the most established and only US Food 
and Drug Administration (FDA)-approved technique for CTC detection in clinical 
applications. Despite its potential (Cristofanilli et al. 2004, Farace et al. 2011), 
CellSearch only demonstrates cancer cell recovery of less than 60% and requires a 
high minimal input volume for disease detection. The efficiency is further reduced 




1.3.2 Physical methods based on cell size and deformability 
The limitations of affinity-binding enrichment techniques led scientists to generate 
label-free methods which can recover a larger distribution of CTCs. Common 
alternatives include filtering whole blood or passing RBC-lysed nucleated cells 
through a filter membrane. To minimize shear stress and increase recovery, many 
forms of membranes have been fabricated, including track-etched membranes (Lee et 
al. 2014) and more recently, three-dimensional (3D) filters (Zheng et al. 2011). 
Another dominant field of CTC enrichment by size works on the passive focusing of 
cells by inertial forces within a microfluidic chip (Di Carlo et al. 2007, 
Kuntaegowdanahalli et al. 2009, Hou et al. 2013, Khoo et al. 2014, Warkiani et al. 
2014a, Warkiani et al. 2014b), whereby larger cancer cells can be rapidly separated 
from the smaller blood cells under continuous flow. Other label-free techniques 
utilizing physical properties for isolation include density gradient centrifugation 
(Gertler et al. 2003) or dielectrophoresis (Gascoyne et al. 2009, Gupta et al. 2012).  
 
The obvious advantage of using a label-free system for the detection of a 
heterogeneous cell population lies in the absence of the need to depend on specific 
antigens for enrichment. Nonetheless, cells enriched from label-free systems will still 
require verification by using markers to identify CTCs and contaminating WBCs 
(Table 1.2).  
  
1.3.3 Techniques based on proliferative capability 
Most CTCs are believed to have short half-lives, and the rest are thought to be 
dormant (Chambers et al. 2002). Not surprisingly, previous attempts to culture these 
cells under conventional methods in ECM-coated culture dishes yielded no positive 
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results. However, the appeal of expanding CTCs remain definite, since culturing 
CTCs will overcome the ‘rare cell’ problem and could also be instrumental in utilizing 
CTCs in actual clinical settings (e.g. drug testing). Expanded CTC populations could 
also provide enough samples to generate insight on cancer biology via profiling or 
characterization of cellular processes.  
 
A study in 2007 demonstrated that some CTCs might be active, through the 
establishment of a protocol that demonstrated active secretion of proteins from 
enriched CTCs (Alix-Panabieres et al. 2007). In the year 2014, a few techniques 
claimed (albeit of low efficiency) the establishment of cell lines from long-term 
culture of CTCs (Table 1.3) (Yu et al. 2014) (Yu et al. 2014) (Yu et al. 2014) (Yu et al. 
2014) (Yu et al. 2014) (Yu et al. 2014). The reported methods often rely on media 
supplemented with growth factors, which might serve to promote the switch towards 
proliferation.  
 
CTCs were not the only rare cell populations that have been cultured. Culture 
techniques of other rare cancer cell types, such as CSCs of tumor origin, have 
previously been explored (Heddleston et al. 2009). These protocols were established 
by mimicking conditions in the tumor microenvironment, such as hypoxia (Casazza et 
al. 2014). At this point of time, researchers had also been successful in culturing 
DTCs from the bone marrow of patients with various cancer types, and they reported 
an inverse correlation of growth potential to patient response (Solakoglu et al. 2002). 
Some used growth factors (e.g. fibroblast growth factor 2), which might be secreted 
by cells in their stromal niche, to propagate DTCs (Alix-Panabieres et al. 2007).  
 
Despite the vast interest gained from these current reports, techniques of CTC culture 
still suffer from many limitations, as will be discussed in Section 1.4. Novel methods 
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of high-throughput, efficiency and reproducibility are required to generate meaningful 
utilities for CTC expansion. Established protocols of CSC and DTC cultures could be 
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1.4 CTC biology and limitations of existing techniques 
Preliminary findings from conventional CTC detection methods have given us a 
glimpse into the phenotype of CTCs, which appear to exhibit intra- and inter-patient 
differences (Vona et al. 2000, Marrinucci et al. 2010, Farace et al. 2011, Navin et al. 
2011, Polyak 2011, Gerlinger et al. 2012, Hou et al. 2013, Khoo et al. 2014). This 
diversity may reflect that of tumors, which are made up with heterogeneous cell 
populations within a primary tumor (intratumor heterogeneity) or between tumors of 
different tissues (intertumor heterogeneity).  
 
Due to this variation of biological phenotypes,  the current standard for CTC 
definition (CK+/EpCAM+/CD45- nucleated cells with high N/C ratio; Section 1.2) is 
not sufficient to describe CTCs, and most techniques end up generating an 
underestimation of the actual CTC frequency in blood. In addition, the reported 
frequency of CTCs further varies with the different techniques used, due to 
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(Khoo et al. 
2014) 
 
1.4.1 Low frequency and marker heterogeneity 
Due to the heterogeneity of CTCs, conventional enrichment methods by affinity 
binding can only be made superior if a unique CTC marker is verified. The current 
use of affinity binding methods for CTC isolation evokes a vicious cycle of 
incomplete CTC detection, preventing the identification of unique antigens for better 
CTC detection.  
 
The markers listed in Table 1.2 for CTC isolation are also expressed by other cell 
types, thus risking the likelihood of detecting false positives, such as circulating 
epithelial cells (CEpC) (Ring et al. 2005) or other bone marrow-derived mesenchymal 
stem cells (MSCs) (Jiang et al. 2002). CEpC are often present in blood of patients 
harboring proliferative disease or inflammation (Goeminne et al. 2000), and cannot be 
depleted by further negative selection with antibodies targeting leukocyte markers 
(Fehm et al. 2005).  
 
False positives can also be incurred by non-specific binding, which is often the result 
of antibody association with normal WBC expressing Fc receptors (Gadd and Ashman 
1983, Riethdorf et al. 2010), or even activated leukocytes expressing EpCAM or 
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cytokeratin (Jung et al. 1998, Kowalewska et al. 2006). Protocols describing the use 
of a CTC enrichment device usually utilize healthy blood samples as negative controls 
to determine the frequency of false positives, and this value has been shown to be 
present in 0-20% of the enriched cell population (Goeminne et al. 2000, Pantel and 
Woelfle 2005). 
     
The markers used for CTC detection are not applicable to all its subpopulations 
(Sieuwerts et al. 2009), partly due to the process of EMT (Thiery 2002). For example, 
EpCAM is only expressed on cells with epithelial or intermediate epithelial 
phenotypes. Hence, techniques which utilize EpCAM as the core antigen for CTC 
recognition (Farace et al. 2011) suffer from a high rate of false negatives (Pantel and 
Woelfle 2005, Sun et al. 2011). In addition, EpCAM may not be a reliable marker for 
epithelial tumors since the association of EpCAM to cellular epithelial state is still 
unverified.  
 
On the other hand, some cancer cells, such as those from triple negative breast cancer 
subtype or others characteristic of normal basal epithelial or adipose cells (Sieuwerts 
et al. 2009), may even cease to express any of the distinct markers used for CTC 
identification. It is apparent that only the use of a combination of markers (Table 1.2) 
will be efficient in detecting a wider coverage of CTCs present in blood (Riethdorf et 
al. 2010, Farace et al. 2011).  
 
In addition to the lack of a definite CTC marker, affinity-based enrichment procedures 
coupled with microfluidics usually operate at low flow rates and are only optimal at 
low cell concentrations (to reduce clogging or clotting issues) (Zheng et al. 2011), 
hence greatly reducing throughput. Viability of the cells is an additional issue, since 
most of these techniques require long processing hours. Overall, the limitations posed 
 24 
by affinity dependent techniques are detrimental to enrichment of rare CTCs.   
 
Recent culture techniques suffer from the same drawbacks as affinity-binding 
methods (Section 1.4) as they require pre-enriched cells obtained from affinity-based 
platforms. Efficiency of these techniques is also low (Table 1.3), and require large 
sample input for culture (8-40 ml whole blood per sample). Hence, a superior and 
efficient method for culture should be developed without the need for pre-enrichment 
procedures. 
  
1.4.2 Variation in morphology, size and other physical properties 
Isolation of CTCs based on physical properties seems to be a promising method for 
solving many problems accompanying the use of affinity binding techniques. Samples 
are usually processed under relatively higher rates, facilitating the speed of which the 
sample can be processed.  
 
In spite of these benefits, high fluid flow within these devices introduces shear stress, 
which can still affect cell viability and may even distort cell morphology. Of the label-
free techniques, devices capitalizing on sorting by size are the most predominant. 
However, CTCs are not all larger than the majority of blood cells. Preliminary 
analysis from various groups reported the observation of Small CTCs within the range 
of 10-20 um, which coincides with the leukocyte size range (Alunni-Fabbroni and 
Sandri 2010). Other cells which do not have resemblance to classic cancer phenotypes 
(e.g. large cells with low N/C ratio present in patients with large cell neuroendocrine 
carcinoma (Hiroshima, 2006 #264)) may also bare malignant properties, and this 
heterogeneity will severely limit the usefulness of size-based enrichment methods.  
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1.4.3 CTCs may be associated to other cell types in blood 
CTCs do not only exist as single cells within the circulation, but have been detected as 
aggregations of 2 or more cells, termed as microemboli. These aggregations could 
have arisen from the tumors directly or were introduced via intravasation of the neo-
vessels (Thiery and Lim 2013). A recent study linked the generation of microemboli 
with a plakoglobin mechanism which induces cell clustering (Aceto et al. 2014), and 
associated the presence of microemboli with initiation of metastasis.  
 
However, most CTC enrichment assays are not able to retain these clusters, due to 
various technical aspects (e.g. high shear rate which breaks up aggregations). Other 
factors include assay design, such as narrow channels in microfluidics, which also 
result in significant loss of microemboli. In this aspect, cultures and size-based 
enrichment techniques can be useful in isolating CTC clusters, which will help verify 
their roles in systemic spread, collective migration (Friedl and Gilmour 2009) and 
correlation with disease prognosis (Friedl and Wolf 2003, Wittekind and Neid 2005).  
 
Besides aggregating with their own, CTCs may also associate with platelets to shield 
themselves from physical fluid shear and immune cells (Kang and Pantel 2013). 
Platelet coating can induce EMT via the secretion of transforming growth factor beta 
(TGFβ) (Labelle et al. 2011), leading to phenotypes favorable for extravasation and 
subsequent tumorigenesis. The close proximity of CTCs with other cell types means 
that these cells are likely to be enriched in the process, leading to contamination that 
can affect downstream analysis. In addition, CTCs surrounded by the platelet cloak 
can also evade detection by antibodies in affinity-binding techniques. 
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1.4.4 CTC release and life cycle in circulation  
Most CTCs exist briefly in circulation (Glinsky et al. 2003), with a majority of them 
being sequestered by narrow vessels within approximately 5 minutes (Luzzi et al. 
1998). It is still not fully understood when and why cancer cells were triggered to 
dissociate from the tumor, but some studies have linked the phenomenon to physical 
trauma near the tumor site (i.e. iatrogenic procedures) (Liotta et al. 1976, Sugarbaker 
1996). Of those CTCs which managed to stay in circulation, some were believed to 
persist in blood for months (Muller et al. 2005, Stott et al. 2010). Insufficient studies 
are available to determine if the time of which the liquid biopsy is obtained will affect 
the correlation of CTC counts to disease parameters. 
 
1.5 Prospects of expanding CTCs for clinical utility  
Early detection of disease is inversely correlated to survival rate (Allard et al. 2004, 
Cristofanilli et al. 2004, Budd et al. 2006). According to the American Cancer Society, 
one-third of patients who undergo regular checkups receive the wrong evaluation on 
their disease status, due to the inability of current diagnostic devices to detect small 
metastases in the body. CTC counts may serve as a valuable and sensitive parameter 
for cancer detection. 
 
However, due to various technical limitations (Section 1.4), there is still no golden 
standard for CTC detection. A consensus on the selectivity, sensitivity and relevance 
of existing CTC detection assays has to be reached for actual clinical utility to take 
place.  
 
CTC cultures are a promising means of amplifying a consistent spectrum of cells 
potentially pivotal for metastasis and disease relapse. An optimized CTC culture assay 
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can provide a sensitive and rapid screening method to determine the presence of 
proliferative cancer cells in patients (Cristofanilli et al. 2004, Hayes et al. 2006, 
Cohen et al. 2008). This can help to identify cancer in the earlier stages or provide 
hints of disease relapse. Expansion of a rare cell cohort can also be used to better 
define the phenotypic and genotypic characteristics without the need for sophisticated 
single cell analytical (SCA) techniques. In addition, CTC cultures can serve to 
amplify the sub-populations amongst the heterogeneous CTCs, and identify the ones 
which would eventually be most important in the process of metastasis. This may help 
clinicians identify novel drug targets for treatment.  
 
The current methods for CTC cultures face three main issues:  
1) CTC cell lines are immortalized phenotypes, and cannot represent primary 
carcinoma cells (Lacroix and Leclercq 2004, van Staveren et al. 2009).  
2) The long periods required for cell line establishment limits clinical utility, since 
early detection and treatment is crucial for patient survival. 
3) Cultures are established at low efficiency and require large sample input. This 
makes it challenging to monitor patient response over different treatment time 
points.  
 
1.6 Hypotheses and project proposal 
Sensitive CTC enrichment could play a dramatic role in shaping strategies for cancer 
detection and evaluation of patient prognosis. The development of a novel and rapid 
assay for the consistent and efficient expansion of primary CTCs is imperative to 
provide actual clinical value to these rare cells. The hypotheses for this thesis project 
are as follows: 
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 Primary CTCs can be expanded efficiently as a short-term culture under suitable 
conditions. 
 Putative CTCs in culture may consist of subpopulations with heightened 
tumorigenic or metastatic potential. 
 Culture phenotypes can correspond to disease severity or patient outcome. 
 
From a mechanobiology purview, the microenvironment of primary cancer cells, such 
as physical topography, cell-cell or cell-substrate interaction, and other cues from 
neighboring cells, is crucial for maintaining cancer cell viability and proliferation. 
Hence, it is expected that CTCs may have to be maintained under an environment 
similar to its stromal niche in vivo to establish culture. Cultured CTCs are likely to be 
heterogeneous and may comprise subpopulations with higher tumorigenic potential.  
 
The scope and objectives of this study include the design and optimization of a short-
term CTC culture relevant to in vivo stromal niche conditions, thus achieving a 
protocol of high efficiency for the proliferation of primary CTCs. The method does 
not require prior processing with any form of enrichment techniques, which greatly 
facilitates ease of operation. The lack of pre-processing also reduces cellular damage, 
thus favoring cell viability and minimizing cell loss. Since an enrichment assay by 
culture selects for all proliferative CTCs, the protocol is flexible and can be adapted 
for expanding CTCs of different cancer types. 
 
To achieve this, microwells were proposed as the main feature of the culture assay 
design. Such topography was previously used to sustain stem cell properties of 
embryonic stem cells (Moeller et al. 2008), and was also reported to affect the 
metabolic activities and differentiation of various primary non-cancer cell types 
(Wang et al. 2009). This project also tested the influence of hypoxia on the 
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establishment of CTC cultures, since low oxygen levels were known to promote CSC 
proliferation (Heddleston et al. 2009).  
 
Optimization of the assay was attempted by testing with a range of microwell 
dimensions and culture conditions, using a breast cancer cell line (SKBR3). 
Confirmation of culture parameters was then established with actual clinical samples. 
To validate the presence of CTCs in culture, cultures were harvested and 
characterized to identify blood cells that might persist in culture. Further on, the 
cultures were profiled by immunostaining, fluorescence in situ hybridization 
(DNA/RNA FISH), histopathological staining and other techniques to ascertain 
viability and to determine their characteristics (e.g. morphology, EMT phenotypes, 
invasiveness and copy number increase in cancer-associated genes). Peripheral blood 
of healthy volunteers was utilized as controls to evaluate the specificity of this method. 
Finally, the data obtained was also used to draw any possible correlations between 






Chapter 2: Materials and Methods  
2.1 Preparation of culture assay 
Microwells were made on non-coated 60 mm polystyrene dishes (Becton Dickinson, 
Franklin Lakes, NJ) in an array pattern which maximized the coverage of microwells 
on the substrate (~48 microwells cm
-2
, Figure 2.1A). The microwell array was drawn 
with the Auto Computer Aided Design software (Fortier et al.) (Autodesk, San Rafael, 
CA). Due to the flexibility of this method, microwells can be produced on other 
polystyrene substrates, including well plates (Figure 2.1B). An air-cooled 10.6 µm 
CO2 laser engraving/cutting system (VLS-2.30, Universal Laser System Inc., 
Scottsdale, AZ) was used for the generation of microwells. Patterned dishes were 
sterilized with and kept in 70% ethanol until use. 
 
2.2 Characterization of biochemical changes of patterned dishes 
To estimate relative surface topography of the dish before and after laser ablation (i.e. 
to determine difference in surface roughness), atomic force microscopy (AFM) was 
used to trace the substrate surface at regions near or away from the microwells (laser-
ablated regions). Scans were performed with the contact mode, in air, using a Bruker 
cantilever optic fiber probe of tip diameter of 20 nm (Msct tip, C triangle cantilever), 
as described in previous reports (Li et al. 2011). Imaging was done with the 
Nanowizard I AFM (JPK Instruments, Berlin), and analyzed with the JPK SPM 
software.  
 
To determine changes in the surface energy after laser treatment, water contact 
measurements were obtained using a self-assembled goniometer consisting of a side-
view microscope and camera (Prof Seeram Ramakrishna’s lab, NUS) (Nikon, Japan). 
An automatic dispensing needle (VICI Precision Sampling, CA, USA) released a 
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single 1 μl water droplet onto the substrate region tested, and images of the water 
droplet were immediately obtained. Water contact angles (WCAs) were estimated 
using the axisymmetric drop-shape analysis profile technique. 
  
2.3 Blood collection 
Informed consent from healthy volunteers and breast cancer patient individuals (see 
Appendix Tables A1.1-1.4) were obtained before blood extraction. Patients were 
participants of four clinical studies, including two neoadjuvant (doxorubicin 
/cyclophosphamide (AC) with or without Sunitinib and paclitaxel /carboplatin/ 
lapatinib), one for refractory patients under assorted treatments, and another which 
involved patients with early-stage breast cancer. All study protocols were approved by 
the institutional review board and local ethics committee (DSRB Reference 2012 / 
00105, 2012 / 00979, 2010 / 00270, 2010 / 00691). Blood samples were collected 
from healthy volunteers for use in the study (DSRB-2013/00542) as controls for 
culture or validation of antibody specificity.  
 
For both patients and healthy volunteers, 10 ml of blood was obtained after discarding 
the first 1 ml of blood collected to avoid contamination by skin fragments. Clinical 
blood samples were either sampled in a single draw or at different treatment time 
points. Collected blood was stored in ethylenediaminetetraacetic acid (EDTA) tubes 
(BD, Franklin Lakes, NJ, USA) at 4 
o
C prior to use. To retain viability of the cells and 
prevent coagulation of blood, blood samples were processed within 8 hrs from the 
time of sampling. 
 
2.4 Maintenance of cancer cell lines 
Human breast adenocarcinoma cell lines, MCF-7, SKBR3 and MDA-MB-231 
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(obtained from American Type Culture Collection (ATCC), were used for initial 
characterization of the culture assay or to validate antibody specificity. Cells were 
cultured in T-25 polylysine-coated tissue culture flasks (Falcon Plastics, Oxnard, 
Calif.) with either Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, St. Louis, 
MO, USA) for MCF-7 or Roswell Park Memorial Institute (RPMI) 1640 (Sigma, St. 
Louis, MO, USA) for SKBR3 and MDA-MB-231 respectively. Media was 
supplemented with 10% fetal bovine serum (FBS) and 1% penstrep (penicillin G and 
streptomycin) (all from Invitrogen, Carlsbad, CA). Fresh media was supplied to the 
cells every 2 days, and passaged upon close to 80% confluency.  
 
Cancer cell line cultures were detached from the wells with the use of trypsin-EDTA 
(Gibco, Carlsbad, CA, USA) after being washed with 1× phosphate buffered saline 
(PBS), and incubated under 37 degrees C for 5 mins. Trypsinised cells were 
neutralized with the same volume of media (as trypsin) and transferred to a 15 ml 
falcon tube (Beckon Dickinson, San Jose, CA), which was then centrifuged at 1200 
rpm for 3 minutes to concentrate the cells. Concentrated cells were split into 3 new 
flasks and incubated in the incubator at 37 
o
C, 5% CO2 and high humidity. 
  
2.5 Cancer cell line cultures for optimization of assay parameters 
Breast cancer cell line SKBR3 was seeded at high concentrations (>10^
6
 cells) into a 
patterned 60 mm dish with or without surface treatment. Cell counts were carried out 
with a disposable hemocytometer (iN Cyto, Republic of Korea) and the cell stock was 
serially diluted till the required amount. Cultures were maintained under conditions 
suitable for cell lines (37°C, 5% CO2, high humidity and normoxia). 
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2.6 Preparation of blood samples for culture 
For certain optimization assays, Ficoll-Paque PLUS (GE Healthcare, cat. no. 17-1440-
02), a reagent commonly used for separation of blood components, was used as 
recommended by supplier. For the rest, RBC lysis was done to obtain nucleated cells 
for culturing. 10 ml of each blood sample was mixed with RBC lysis buffer (1:3 ratio; 
Life Technologies, Carlsbad, CA) under gentle agitation for a maximum of 5 mins, 
and centrifuged at 1000 g for 5 mins to concentrate the intact nucleated cells (Figure 
2.2). Supernatant containing lysed RBC debris and plasma were decanted, and the 
resultant cell pellet was immediately washed once with PBS. Cell suspension was 
again centrifuged and eventually resuspended with fresh supplemented DMEM media. 
In the optimized protocol, the final volume of nucleated cells was split into four 
portions and seeded into four individual 60 mm patterned dishes for culture. 
 
 
Figure 2.2 Preparatory procedures before culture. Whole blood was collected from 
healthy volunteers or patients via venipuncture. Collected blood was lysed with RBC 
lysis buffer to concentrate the nucleated cell fraction, which contained WBCs and 
CTCs. These cells were seeded onto patterned culture dishes with microwells for 
culture.  
 
2.7 Primary human CTC culture 
Seeded patterned dishes were kept in the humidified incubator maintained at 37 °C in 
5% (v/v) CO2 and 1 % O2. Fresh media (supplemented DMEM) was introduced every 
2 days, and media change was carried out gently at a consistent position of the dish to 
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reduce turbulence and disturbance to cell clusters. For proliferative cultures, media 
change intervals could be reduced to every 24hrs. Culture conditions might vary for 
certain experiments, due to the need for assay optimization (e.g. 21% O2, normal 
dishes or RPMI instead of 1% O2, microwells, or DMEM). During harvesting, clusters 
were lifted from the microwells with adequate washing (pipetting) with PBS, aided 
with dissociation using 0.01% trypsin and 5.3 mM EDTA (Lonza, Basel, Switzerland) 
solution in PBS, under 3 min incubation at 37 °C.  
 
2.8 Cluster formation, imaging and diameter measurements  
Viable cultures could be maintained within microwells up to 2 months or further 
passaged in suspension or gel assays (see Section 4.2.4) to form spheroids. Cultures 
were harvested or imaged with phase contrast microscopy (Nikon, Japan) at Days 8, 
14 or 21. Average cluster diameter can be obtained using ImageJ (NIH, Bethesda, 
MD), by averaging the maximum and minimum length along a single Z plane for each 




Figure 2.3 Measurement of average diameter for (A) clusters and (B) single cells. 
The maximum and minimum lengths along a single Z plane for each object were 
obtained and the average value calculated to get the average diameter values. Scale 
bar is 50 μm for (A) and 20 μm for (B). 
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2.9 Flow cytometry to determine proportion of viable cells  
Proportion of viable cells was estimated by propidium iodide (PI) (Sigma-Aldrich) 
staining. Dead cells were stained by PI, leaving live cells unstained. Freshly harvested 
cells were incubated with PI on ice for 15 mins, washed thoroughly and processed 
with Accuri C6 (BD bioscience). Cells were gated based on PI expression and the 
resulted cell counts obtained with a data analysis program (BD CFlow Plus Software 
(Accuri)).  
 
2.10 Histological staining of size-sorted cultured cells 
Histopathological morphology of the cultured cells was observed via standard 
Papanicolaou (PAP) staining procedures at the Advanced Molecular Pathology 
Laboratory of Institute of Molecular and Cell Biology (IMCB; Singapore). PAP stain 
is a cytological technique adopted to distinguish phenotypes of cells via the 
differential staining of various cellular components.  
 
Staining was done on frosted slides (Thermo Fisher Scientific) containing cytospots. 





 cells). The cell suspension was added into a Cytospin 4 cytocentrifuge (Thermo 
Fisher Scientific) and spun via centrifugation at 600 rpm for 5 min, to generate 
concentrated cell spots. 
 
To better contrast the morphology between cultured cells of different sizes, harvested 
cultures were first size-sorted by a spiral inertial microfluidic biochip as previously 
described (Hou et al. 2013). The device allowed the pumping of cell suspension 
through this microfluidic biochip at 100 µl min
-1
 together with the sheath fluid (PBS) 
to allow separation of cells above ~20 µm from the smaller cells. The size-sorting 
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principle was based on dominant inertial forces in a curvilinear channel, allowing the 
focusing of particles of varied sizes at different positions within the microchannel, 
followed by subsequent retrieval at separate outlets. The small and larger cells were 
cytospun separately onto the slides as described for PAP staining or Diff-QUIK 
Romanowsky staining (Pathology Department of the National University Hospital, 
Singapore). Diff-QUIK is another common histological staining method for 
distinguishing different cell populations, including blood smears. 
 
2.11 Enumeration of putative CTCs 
To estimate the amplification of CTCs in culture, cells were sampled at Day 0 before 
culture and at Days 8, 14 and 21 of culture. The current definition of CTCs 
(CK+/CD45-/Hoechst+) was used to provide an estimate of the number of CTCs 
present at each time point (see Section 1.2). It is important to note that these counts 
will be an underestimation of the actual CTC numbers, due to the heterogeneity of 
cancer cells.  
 
Cytospun slides were prepared and fixed with 4% paraformaldehyde (PFA) (Sigma-
Aldrich, St Louis, MO) and incubated at 10 min under room temperature. Fixed cells 
were permeabilised with 0.1% Triton X-100 (Thermo Fisher Scientific) for 1 min and 
stained with a cocktail of antibodies targeting cytokeratins 8, 18 and 19 (Pan-
cytokeratin) and CD45 (all from Miltenyi Biotec, Auburn (MACS), CA) (diluted at 
1:100 with 2% bovine serum albumin (BSA)) for 30 mins under dark conditions. The 
cell spot was washed extensively to remove unbound antibodies and reduce unspecific 
binding. Cell nuclei were labeled with Hoechst dye (Invitrogen, Carlsbad, CA). 
Cytospots were imaged with an upright epifluorescence microscope (Nikon, Japan) to 
quantify the CK+/CD45-/Hoechst+ cell counts ml
-1
 of blood. 
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2.12 Immunophenotyping of cell clusters 
For direct staining of cell clusters, media was removed gently from the dish and 
clusters were fixed and permeabilized (as described in Section 2.12) directly within 
the microwells. Permeabilized cell clusters were then incubated with the respective 
antibody cocktail solution diluted in PBS/2% BSA for at least 2 hrs on ice. For 
respective dilution factors, refer to (Tables 2.1 - 2.2). For non-conjugated antibodies, 
primary antibodies were added accordingly (Tables 2.1 - 2.2) followed by the 
corresponding secondary Dylight 488 nm or 594 nm antibodies (Abcam, Cambridge, 
United Kingdom). Stained samples were washed with PBS and imaged under an 
















Table 2.1 List of primary antibodies targeting MSC-derived cell types, WBCs 
and endothelial cells. 
Cell type Target Company Isotype Specificity Dilution 
MSC 
derivatives 





1 to 250 





1 to 250 
Osteocyte Osteocalcin  Abcam 
IgG 
(Rabbit) 
Human 1 to 250 
































1 to 250 
Monocytes 
CD14  Abcam IgG (Goat) 
Human 
1 to 250 
CD16  Abcam 
IgM 
(Mouse) 







1 to 250 
NK cells CD56 Abcam 
IgG 
(Rabbit) 
Human 1 to 250 






1 to 250 
Endothelial cell  CD31 BD 
IgG1 
(Mouse) 




Table 2.2 List of primary antibodies targeting antigens expressed by a variety of 
stem cells or epithelial cells or mesenchymal cells, including an antibody to 
decorate actin microfilaments and another for cell proliferation status 
Cell type Target Company Isotype Specificity Dilution 

















1 to 250 
CSC 




1 to 100 




1 to 100 
MSC CD90 Abcam IgG (Rabbit) Rat, Human 1 to 250 
HSC CD34 BD 
IgG2a, κ 
(Rat) 
Mouse 1 to 250 
Epithelial cell 
E-cadherin Abcam  IgG1 (Rat) 
Mouse, Dog, 
Human 
1 to 250 
          




1 to 100 
CK 5 Abcam IgG (Rabbit) 
Mouse, 
Human 
1 to 250 






1 to 250 
CK 8 Dako 1 to 250 
CK 18 Dako 1 to 250 
CK 19 Dako 1 to 250 











1 to 250  




1 to 250 
 
2.13 Characterization of putative CTCs via immunophenotyping of cytospots 
Cytospots of cultured cells were stained for 30 min at room temperature, using 
antibodies listed in Tables 2.1 and 2.2. Other cell types, including those of embryonic 
stem cells (ESCs), MSCs, blood cells (Day 0 nucleated cell portion after RBC lysis), 
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macrophages, endothelial cells and human breast cancer cell lines (MCF-7 and MDA-
MB-231) were utilized accordingly as the relevant controls to determine antibody 
specificity or to act as a comparison for antigen expression with putative CTCs.  
 
Senescence-associated beta-galactosidase (SA -gal) activity was investigated in 
triplicates at pH 6 for the quantification of non-senescent cells. Cells were freshly 
lifted from the culture dishes, and fixed with 4% PFA for 10 min. Fixed cells were 
incubated overnight with SA -gal staining solution adjusted to pH 6. Senescent cells 
appeared blue-green while non-senescent cells remained unstained.  
 
For quantification of the proportions of residual blood cells, cytospots were prepared 
with Day 14 samples and stained with the respective antibodies targeting the blood 
cell antigen. Stained slides were imaged and enumerated to determine percentage of 
cells positive for the blood cell marker over total cell count (Hoechst positive cells). 
 
2.14 RNA extraction, reverse transcription and Real-Time PCR quantification 
Cells were lysed with RLT buffer included in the RNeasy MiniPrep kit (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. Cell lysates could be 
frozen at -80°C until further use. Lysates were processed to extract RNA according to 
the full protocol. RNA concentration was quantified with a NanoDrop 
Spectrophotometer (Thermo Fisher Scientific). Complementary deoxyribonucleic acid 
(cDNA) was synthesized from 300 ng of total RNA using the SuperScript™ III First-
Strand Synthesis SuperMix for real-time quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) kit (Invitrogen, Carlsbad, CA), according to recommended 
protocol and stored at -80°C until required.  
 
Six genes (ZEB1, CD44, Vimentin (VIM), CD24, EPCAM and E-cadherin (CDH1)) 
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were selected to distinguish between epithelial and mesenchymal phenotypes. 
Subsequently, genes for HIF1- and SNAIL were used to evaluate mechanisms of 
CTC proliferation. Beta-actin was used as an endogenous control to normalize data. 
The primers used in this assay were from 1
st
 Base (Singapore) and the base sequences 
are provided in Table 2.3. Two other genes (CD45 (PTPRC) and CD31 (PECAM1)) 
were selected to assess the relative proportion of WBCs and endothelial cells as 
compared with nucleated blood cells after RBC lysis. qRT-PCR was performed using 
a 7300 Sequence Detection System (Applied Biosystems, Foster City, CA) with 
SYBR Green (Invitrogen, Carlsbad, CA). PCR reactions were performed in a 96-well 
optical plate, with cycle conditions as follows: 95°C for 20 s, then 40 cycles of 95°C 
for 10 s and 60°C for 20 s. The threshold cycle (CT) was defined as the fractional 
cycle number at which the fluorescence passes the fixed threshold. CT values were 




Table 2.3 List of qRT-PCR probes 






































































2.15 DNA FISH  
Freshly prepared cytospots were fixed with a 400 μl mixture of acetic acid and 
methanol (1:3 ratio, Sigma-Aldrich) at room temperature. Fixed slides were 
dehydrated in a graded ethanol series (80%, 90%, and 100%) using a coplin jar 
(Wheaton Industries, USA), dried and incubated with 4 mg ml
-1
 RNase (Sigma-
Aldrich) in PBS within the humidified incubator at 37 °C for 45 min. Treated slides 
were washed thoroughly under shaking conditions with 1× PBS/0.2% Tween-20 
thrice for 5 mins each, and denatured at 80°C for a maximum of 10 min in 70% 
formamide/2× saline sodium citrate (SCC) (Sigma-Aldrich) solution. Denatured slides 
were quickly chilled with a second round of graded ethanol series on ice, dried and 
then hybridized with either one or all of the pre-denatured probes (Spectrum Green or 
Spectrum Orange) (75°C for 5 min) (Table 2.4) overnight at 42 °C, as recommended 
by the supplier. These slides were sealed by applying rubber cement and kept under 
dark and humid conditions.  
 
Hybridized slides were washed after 16 hours of incubation with 50% formamide/ 2× 
SSC pre-warmed solution (42 °C) thrice for 5 mins each under shaking conditions. 
This was then followed with further washing with pre-warmed 2× SSC solution 
(42 °C), and washed slides were counterstained with Hoechst (33342) dye for 1 min. 
Preservation of the fluorescence signals was done by applying Vectashield® mounting 
medium (Vector Laboratories, Burlingame, CA) before the glass coverslip was 
secured (Thermo Fisher Scientific) and sealed with transparent nail polish.  
 
Hybridized slides were imaged with an upright epi-fluorescence microscope at 63X 
magnification (oil immersion) controlled by Metamorph software. Z-stacks were 
obtained and processed to get a compressed image (by maximum intensity) using 
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Image J. Single DNA spot signals were identified by subtraction of 
background. Proportions of cells displaying signals were compared to total cell count. 
  
Table 2.4 List of DNA FISH probes 









Abbott Abbott Kreatech 
Chromophore Red Red Red Red Red Red Green 
 
2.16 RNA FISH 
The procedure for RNA FISH is similar with that described for DNA FISH. In this 
project, custom-made probes (Table 2.5) were obtained from Affymetrix (iDNA, 
Santa Clara, CA) and the full procedure was carried out with the 
Quantigene ViewRNA Cell Assay kit from Affymetrix as recommended. The target 
genes were selected based on the analysis of various breast cancer expression 
profiling databases (Akalay et al. 2013, Tan et al. 2014), in which the ones 
corresponding to either the highest or lowest EMT scores were selected to 
characterize the cells. Probes targeting epithelial cells were labeled green (488 nm 
excitation wavelength), while those selective for mesenchymal cells were labeled red 
(550 nm excitation wavelength). All labeled probes were incubated with a single 
sample to provide a striking contrast of the EMT phenotype in the sample tested 
(mostly red spot signals = mesenchymal-associated phenotypes; mostly green-
associated phenotypes = epithelial). Washed hybridized slides were counterstained 
with Hoechst (33342) dye and sealed with transparent nail polish after application of 
mounting medium.  
 
Hybridized slides were imaged as described in Section 2.16. In the case whereby 
single spots cannot be identified (due to saturation of probes), epithelial cells were 
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identified as those displaying green signals in the cytoplasm. Cells with intermediate 
EMT phenotypes will display green cytoplasmic signals with red dot signals. 
 
Table 2.5 List of RNA FISH probes 
Specificity Probes Company Chromophore 
Epithelial cells 
E-cadherin iDNA Green 
TFF1 iDNA Green 
FOXA1 iDNA Green 
AGR2 iDNA Green 
GATA3 iDNA Green 
CK 7 iDNA Green 
CK 8 iDNA Green 
CK 18 iDNA Green 
CK 19 iDNA Green 
Mesenchymal cells 
Fascin iDNA Red 
Vimentin iDNA Red 
PTX3 iDNA Red 
SERPIN2 iDNA Red 
 
2.17 Validating presence of residual macrophages with a phagocytosis assay 
Day 14 cultures were introduced evenly with high concentrations of fluorescein-
labeled polystyrene microbeads (1 µm; Roche Applied Science) and incubated 
overnight under optimal culture conditions. After incubation, excess microbeads were 
removed by gentle washing with PBS, followed by fixation and imaging as previously 
described with confocal microscopy (Section 2.13).  
 
2.18 Establishment of spheroids from cultured CTCs  
Day 14 cultures were passaged with trypsin-EDTA as described (Section 2.4), 
followed by seeding into 3D Geltrex® (Invitrogen, cat. no. 12760-013) within wells 
of 16-well glass chamber slides (Lab-Tek Products, Miles Laboratories, Naperville, IL) 
or 48-well plate chambers. Dissociated cells could also be cultured in 2D ultra-low 
adhesive dishes (Cat No; 3473 or 3473; Corning Inc., Corning, NY). Passaged 
samples were allowed to proliferate under optimal conditions for another week, fixed 
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then stained with either Tetramethylrhodamine (TRITC) -phalloidin (Dilution 1:1000, 
Sigma) or CK/CD45, coupled with Hoechst counterstaining. To trigger spheroid 
formation for established cultures, passaged cells were maintained with advanced 
DMEM/F12, reduced-serum medium (Ratio 1:1) (Gibco, Life Technologies, Carlsbad, 
CA) under normoxia, and could be passaged up to 5-6 times. 
 
2.19 Invadopodia assay and phalloidin staining 
Cultures were harvested and added (density of ~ 10
4
 cells per well) to a thin layer of 
FITC-labeled gelatin in 8-well glass bottomed Lab-Tek (Nunc, Thermo Scientific) 
chamber slides. Cancer cell lines were handled separately in the same manner as a 
control. Gel matrix was obtained from the QCM Gelatin Invadopodia Assay Green 
(Millipore) kit. Seeded samples were incubated overnight and then fixed with 4% 
PFA, permeabilized and stained with phalloidin-rhodamine (Invitrogen) for 2 hrs. 
Stained samples were counterstained with Hoechst dye for 15 mins. Samples were 
imaged at 20X using an inverted confocal microscope (Olympus Fluoview FV1000, 
USA) and representative images were analyzed with ImageJ. Cell count and area of 
degraded matrix were obtained and contrasted for each sample. 
 
2.20 Western blot 
Samples were lysed within the dish with cold RIPA buffer from the NE-PER Nuclear 
and Cytoplasmic Protein Extraction Reagent kit (Pierce, Rockford, IL, USA). The 
protein concentration was compared to protein standards and estimated with 
components from the Bradford Protein Assay Kit (Bio-Rad). Purified protein was 
extracted and 20-50 µg of protein was processed with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), transferred electrophoretically to 
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nitrocellulose membrane (Millipore Corp., MA, USA). Membranes were blocked with 
5% milk for an hour then incubated with the respective antibodies overnight. This was 
followed by washing and further incubation for 1 hr at 25 °C with horseradish 
peroxidase (HRP) -tagged secondary antibody (GE Healthcare), before imaging 
(VersaDoc imaging system; Bio-Rad, Hercules, CA). Beta-actin protein level was 
similarly detected to confirm equal loading. 
  
2.21 Cell cycle analysis 
Harvested cells were fixed with cold 70% ethanol, treated with 10 μg ml-1 RNase A 
(30 min at 37 °C) and incubated with PI for 30 min at room temperature. Stained cells 
were washed thoroughly and processed in a flow cytometer (LSRII; Becton Dickinson, 
Heidelberg, Germany). Analysis were done with a FL2-A (585/40) filter. To estimate 
the positions of G0/G1, S and G2 on the charts, a cancer cell line with known 
polyploidy (MDA-MB-231) was processed in a similar manner as a form of control. 
An event count of 10000 was used for all experiments.  
 
2.22 Statistical analysis 
The χ2 (chi) test was used to access any associations between various variables (Table 
5.1) with microwell cell cluster formation. For larger sample sets, verification was 
done with a two-way analysis of variance (ANOVA) for the two independent 
variables (culture positivity and patient survival status) (Finak et al.). 95% confidence 
intervals were determined. Adjusted multivariate analyses for continuous independent 
variables (to other variables) require larger sample sizes and were not utilized in this 
study. Further Cox regression (investigation of multiple variables) was also not 
carried out due to the small sample size. Based on previous studies, the minimum 
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Chapter 3: Microwell-based Culture and Expansion of Viable 
CTCs 
 
3.1 Optimization of culture conditions  
3.1.1 Microwell dimensions and surface treatment 
Microwells were generated on uncoated dishes with a laser ablation technique, which 
provided the speed of fabrication (one 60 mm dish in ~20 mins) and the versatility of 
varying microwell dimensions for optimization. The microwell size could be varied 
with laser power, speed of ablation and focal plane (distance of laser from substrate) 
used during ablation (Figure 3.1A).  
 
An invasive breast cancer cell line of enhanced spheroid-forming capability (SKBR3) 
was used for these optimization experiments. Small microwells of average 50 µm 
inner diameter were initially generated (using long focal length and low power), with 
negligible layer of recast (Figure 3.1B (left; main and insert)). However, these 50 
µm wells were too small and shallow to capture and retain seeded cells after media 
changes (disturbance and removal during media change). This is similar for large and 
wide wells of average inner diameter 341.5 um (Figure 3.1B) (using minimal focal 
length possible and high power). Hence, microwells of intermediate sizes are required. 
Since it is difficult to fine-tune the focal plane quantitatively (to obtain microwells of 
intermediate sizes), the focal distance was fixed at the minimal distance possible for 
the laser to be positioned away from the substrate.  
 
Microwells of intermediate sizes were then fabricated by variation of laser power and 
ablation speed (Figure 3.1C). Higher power percentage and lower speed percentage 
values for the laser were desired to obtain deeper microwells, as the percentage of 
laser power correlates positively with depth, and the percentage of speed correlates 
negatively with depth. Deeper wells serve to reduce the disturbance of non-adherent 
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Figure 3.1 Optimization of microwell fabrication. (A) Schematics illustrating the 
formation of a microwell. The distance of the laser from the substrate, speed of laser 
ablation as well as laser power affects the depth and width of microwell formed. The 
higher the laser power, the deeper and wider the resultant microwell becomes. The 
layer of recast is an artifact generated by the laser process, which becomes prominent 
with stronger laser power. (B) Phase contrast images of the smallest (left; average 
inner diameter 50 µm; Scale bar is 50 µm) and largest possible microwell that can be 
fabricated (right; average inner diameter 341.5um; Scale bar is 100 µm.) (C) (Left) 
Microwells of different dimensions can be created by varying laser power and 
ablation speed. Average inner diameter of the microwells was obtained by averaging 
the length and breadth dimensions as shown in insert of left image. 50% power (when 
speed is standardized at 10%) yields the smallest microwells. (Right) 10% speed 
(when power is standardized at 50%) yields the smallest microwells. Focal plane is 
fixed to the minimal possible distance of the laser away from substrate. 
 
With an uncoated substrate, most SKBR3 cells were washed away from the larger 
microwells (~341.5 µm), while a majority of cells were retained in the smaller 
microwells (~107 µm and 187.5 µm) (Figure 3.2A). Coating of surfactants (e.g. 5% 
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BSA or pluronic acid) reduced cell-substrate interaction, thus preventing any degree 
of adhesion of cell lines and indirectly promoting formation of cell aggregates or 
spheroids in smaller microwells (~107 µm and 187.5 µm). Spheroid formation was 
more apparent in microwells of average inner diameter ~187.5 µm, possibly due to 
the higher amount of cells captured in wells. For larger microwell dimensions (~341.5 
µm), only a high seeding cell density (>50 x 10
6
 cells), used in addition to surfactant 
treatment, would result in cluster formation. However, the surfactant coating effect 
was temporary, and spheroids obtained from cell line cultures would start to disperse 
after three days in culture (Figure 3.2B). 
 
Using microwells of ~187.5 µm in inner diameter, clinical samples containing 
putative CTCs were processed and seeded for culture under conditions recommended 
for the proliferation of CSCs (1% hypoxia) (Heddleston et al. 2009, Soeda et al. 2009). 
It was observed that the resultant clusters from clinical samples did not behave like 
spheroids generated from robust cell lines. Clusters obtained from blood samples were 
loose clusters, unlike tightly packed aggregates or spheroids (Figure 3.2C). 
Surfactant treatment was also not required for cluster formation from clinical samples, 
due to the lower adhesive capability of cells from the clinical samples. Since blood 
samples were likely to require longer culture periods to obtain clusters, surfactants 
cannot be opted for use in the protocol. This section determined that non-coated 
microwells of ~187.5 µm in inner diameter, fabricated at 10% speed and 50% laser 






Figure 3.2 Optimization of assay parameters with SKBR3 breast cancer cell line. 
Images were obtained with a 20X objective lens. (A) Phase contrast images of 
SKBR3 cells seeded into wells of different average diameters (~107 µm and 187.5 
µm and 341.5 µm). Surfactants (5% BSA and pluronic acid) were used to treat 
patterned substrates respectively. Scale bar is 50 µm. (B) Surfactant treatments of 
substrates is temporary, and spheroids of cell lines cultured in microwells dispersed 
after three days in culture. Scale bar is 50 µm. (C) Clinical samples can form loose 
clusters with microwells of 187.5 µm diameter in the absence of surfactant treatment. 
Scale bar is 50 µm.  
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3.1.2 Characterization of microwell surface chemistry 
The patterned dish was characterized to determine changes in the substrate 
biochemistry induced by laser ablation. The effects of substrate roughness (induced 
by even nano-topographies) on cell proliferation and migration have been disputed 
(Biggs et al. 2010, Nikkhah et al. 2012), but some studies report weakened cell-
substrate adhesion and heightened proliferation of cells on substrates exposed to laser 
(Hao et al. 2005).  
 
AFM was first utilized to trace the roughness of the substrate surface near and away 
from the laser-ablated regions, and graphical representations of the substrate surface 
were constructed accordingly (Figure 3.3A). The regions nearer to the microwells 
were found to be significantly rougher than those further from the laser-ablated 
regions (Figure 3.3B, p < 0.05). Using WCA estimates, it was found that the regions 
nearer to the microwell had increased contact angles, demonstrating higher 
hydrophobicity (Figure 3.3C). The combination of high hydrophobicity and 
roughness may promote protein adsorption and increased cell-substrate interactions 
(Lampin et al. 1997, Mager et al. 2011), possibly aiding the initial clustering of cells 
within the microwell regions and reducing loss of target cells to the non-microwell 




Figure 3.3 Characterization of laser-ablated surfaces to determine changes in 
surface chemistry. (A) Image reconstruction of the substrate surface after scanning 
with AFM on contact mode in air. (B) Graphical representation demonstrating the 
significant increase of average roughness for laser-ablated regions as compared to 
non-ablated regions. Single asterisk indicates P < 0.05 as compared to average 
roughness of non-ablated regions. All error bars represent standard deviation (SD) of 
triplicates. (C) WCA estimates for regions adjacent to or away from microwell 
regions (above). Cells seeded in a patterned dish tend to collect in regions within and 
surrounding the microwells, as compared to regions further away from the microwell 
(below) Scale bar is 100 um. 
 55 
 
3.1.3 Culture preparation and maintenance  
3.1.3.1 Length of culture period 
To establish the optimal length of culture period, clinical samples (10 ml separated 
equally into four 60 mm patterned dishes) were harvested at Day 0, 8, 14 and 21 to 
determine the proportion of proliferative putative CTCs using proliferation marker Ki-
67 (Figure 3.4A). Proportion of Ki67+/CD45- cells increased with culture, being 
highest at Day 14 (27.7%), which is at a proportion comparable to that of most cell 
lines and breast tumors (~20%) (Zabaglo et al. 2003, Rhodes et al. 2010, Machowska 
et al. 2014).  
 
To determine if this time point corresponded to the highest proportion of putative 
CTCs, immunostaining of CK+/CD45- cells were carried out with cytospots prepared 
from either Day 0 (RBC-lysed nucleated cells) or Day 8, 14 and 21 cultured cells. 
Small CK+/CD45- cell counts with respect to total cell counts increased in culture 
over time (Figure 3.4B), especially from Day 0 to Day 8 and Day 14 in culture.  
 
The proportion of Small CK+/CD45- cells beyond Day 14 was observed for most 
samples (70%, n=10) (Figure 3.4C). This could be due to decreased CK expression 
after EMT, and the proportion of EMT phenotypes may vary with cancer type (see 
Section 4.2). Since the time-point with highest CK+/CD45- proportion for most 
samples correlated with the highest number of Ki67+ cells, thus subsequent cultures 





Figure 3.4 Determining time point for culture characterization. (A) Staining of 
proliferation-associated marker, Ki67 at pH 6, for cultures of clinical samples. 
Proportion of Ki67+/CD45- cells for cultures at different time points (Day 0, 8, 14 
and 21) were shown. Representative images of cells stained with CD45- Fluorescein 
isothiocyanate (FITC), Ki67-Alexa Fluor 628 and Hoechst are embedded in top left 
and right boxes respectively. Scale bar is 20 μm. All error bars represent standard 
deviation (SD) of triplicates. Single asterisk indicates P < 0.01. (B) Representative 
images of cells harvested at different culture time points (Day 0, 8, 14 and 21) and 
stained with pan-cytokeratin antibodies targeting CK8, 18 and 19. Scale bar, 20 μm. 
(C) Percentage of Small CK+ cells (15–25 μm) with respect to total cell count 
(Hoechst+) at various time points (Days 0, 8, 14 and 21). Significant expansion of 
CK+ cells can be observed by Day 14. Single asterisk indicates P < 0.01. 
 
3.1.3.2 Preparation of nucleated cell fraction 
Nucleated cells can be obtained from blood samples either after Ficoll gradient 
centrifugation (Martin-Ramirez et al. 2012) or RBC lysis (Khoo et al. 2014). To 
determine which procedure is more suitable for the cultures of clinical samples, 
samples were split into two equal portions and cultured after Ficoll Paque reagent 
treatment or RBC lysis buffer processing. Samples processed with RBC lysis yielded 
larger clusters than Ficoll-Paque processed samples (possibly due to lower cell loss) 
(Average cluster diameter of samples after Ficoll-Paque processing = 52.1 ± 7.5 um; 
Average cluster diameter of samples after RBC lysis processing = 85.4 ± 17.5 um; n = 
3 each) (Figure 3.5A), and the resultant cell counts were also lower in cultures 
obtained after Ficoll-Paque processing (Ficoll-processed to lysis-processed: 0.7:1; 
Figure 3.5B). There was also no significant difference in the proportion of residual 
white blood cell portion (CK-/CD45+) cells observed (Figure 3.5C-D). 
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Figure 3.5 Optimization of pre-processing procedure to obtain nucleated cells for 
culture. (A) Blood samples were processed with either Ficoll-Paque reagent or RBC 
lysis buffer, and then cultured for two weeks. Heightened cell loss was observed with 
the Ficoll Paque technique, leading to smaller clusters. Scale bar is 50 um. (B) 
Graphic representation of the cell count after culture, normalized to the cell count of 
cultures obtained with lysis buffer. All error bars represent standard deviation (SD) of 
triplicates. (C) No significant difference in the presence and proportion of residual 
CK-CD45+ (white blood cell) cells was observed. Scale bar is 20 um. (D) Graphical 
representation of proportion of residual CK-CD45+ portion. All error bars represent 
standard deviation (SD) of triplicate cultures from the same sample. 
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3.1.3.3 Culture media and incubator conditions 
Cultures of clinical samples were maintained with a range of different media to 
determine the influence of different components on CK+ and CD45+ proportions. A 
series of samples were split and separately cultured with growth factor Il6 (at 10ng/ml 
or 20mg/ml), conditioned media (from endothelial cell, MSC or WBC) or RPMI 
medium. Resultant cell cultures at Day 14 were stained for various markers associated 
with epithelial cancer types (CK) or leukocytes (CD45) and their proportions were 
normalized with those obtained from cultures maintained with DMEM media (Figure 
3.6A). Overall, there was some reduction in the CD45+ cell counts in cultures 
maintained with conditioned media or Il6-supplemented media, as compared to those 
in DMEM. However, these differences were not significant (P value = 0.104578, 0.9-
1.2 fold change). Hence, DMEM media was continued for use in subsequent cultures.  
 
To determine the importance of microwells (W) and hypoxia (H) for promoting 
putative CTC expansion from clinical samples, blood samples were split into different 
dishes and maintained under varying conditions. Day 14 cultures were harvested and 
stained with pan-CK, CD45 and Hoechst. Blood cells (CK-/CD45+) were present in 
all four conditions, but the H+W+ condition yielded the highest proportion of putative 
CTCs (CK+/CD45- cells) (Figure 3.6B-C). CK+/CD45+ cells were also found in all 
conditions, and were later found to comprise mainly of reactive leukocytes or 
macrophages (see Figure 3.12). Multilayered clusters were only formed under the 




, and only 
a monolayer of CK+CD45+ or CK-CD45+ cells were found in the microwells under 
normoxia (residual blood cells) (Figure 3.6D). These demonstrated that both hypoxia 
and microwells were required for establishing multilayered clusters comprising of 




Figure 3.6 Determination of media and incubator conditions for putative CTC 
culture. H: Hypoxia (1% O2) and W: Microwells. (A) Representative graph 
demonstrating the proportions of putative CTCs (CK+/CD45- cells) and leukocytes 
(CD45+ cells). CD45+ cell counts were reduced in conditioned media as well as Il6-
supplemented media. However, the differences were not significant. All error bars 
represent standard deviation (SD) of triplicates. (B) Representative images of pan-
CK-FITC/CD45-APC stained cells from cultures maintained under different 
conditions. Cells from cultures maintained under H-W-, H-W+ or H+W- conditions 
had CK+/CD45+ cells, but there were likely to be blood cells such as reactive 
leukocytes or macrophages. These cells formed only a minority proportion in H+W+ 
cultures (not shown). Scale bar is 20 μm. (C) Representative bar chart demonstrating 
the proportion of putative CTCs (CK+/CD45-) after culture under different conditions. 
All error bars represent standard deviation (SD) of culture triplicates obtained from 
different samples. Asterisks indicate p < 0.05. (D) Phase contrast images of Day 14 
cultures under different culture conditions. Multilayered clusters were only formed in 
the presence of microwells under hypoxia. In microwells under normoxia, only a 
loose monolayer of cells (possibly blood cells) was found. No clusters were obtained 
under H-/W- condition. Scale bar is 50 μm. 
 
To determine the volume of blood that should be cultured in each 60 mm patterned 
dish, six samples obtained from advanced metastatic breast cancer patients before 
treatment were cultured in patterned dishes to determine the volume threshold 
required for the detection of a positive sample. Smaller dishes (35 mm) were utilized 
for these experiments to enable the same sample to be used while comparing different 
parameters.  
 
Different volumes of each sample (0.6-1.5 ml) were added to the dishes with ~ 9 cm
2 
surface area. Proportion of microwells with clusters obtained from each sample were 
tabulated (Figure 3.7A). As a preliminary screening, samples with cluster formation 
in ≥50% of ten microwells for 3 out of 4 of sample volume used were regarded as 
positive. The proportion of clusters present in positive (≥50%) and negative (<50%) 
samples was then compared with more elaborate quantification (n=120). Analysis of 
the median values of overall cluster formation proportion in positive and negative 
samples provided confirmation that a threshold of ≥50% (Median of positive samples 
= 72.0%; Median of negative samples = 23.1%; Average of median values from 
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positive and negative samples = 52.1%) could be used to quantitatively distinguish 
between positive and negative samples (Figure 3.7B).  
 
To evaluate the volume of blood required per cm
2 
of culture substrate, the rate of false 
positives from negative samples and false negatives from positive samples (using the 
threshold of ≥50%) obtained from cultures established with different blood volumes 
were tabulated. Samples obtained from 1 ml sample correspond to the minimal 
number of false positives and false negatives. Hence, it was established that the 
minimum volume of patient blood required to correctly evaluate a sample was 1 ml 
per 9 cm
2
, which corresponds to ~2.3 ml of blood for a patterned 60 mm dish (Figure 
3.7C). For all subsequent experiments, 10 ml of clinical blood sample were separated 
and cultured in four 60 mm patterned dishes (2.5 ml each). 
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Figure 3.7 Estimation of the minimal sample volume required for clinical sample 
culture. (A) Proportion of microwells with clusters. Samples with cluster formation 
in less than 50% of microwells using most volume amounts (3 out of 4) were 
considered negative. (B) Confirmation of threshold (Average of median values from 
positive and negative samples = 52.1%) using a box plot. Median of positive samples 
= 72.0%. Median of negative samples = 32.1%. Single asterisk indicates P < 0.01. (C) 
Table listing false positives from negative samples and false negatives from positive 
samples. Samples obtained from 1 ml sample correspond to the minimal number of 
false positives and false negatives. Single asterisk indicates P < 0.01. 
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Section 3.1.4 Section Summary and Discussion 
Section 3.1 described the optimization of culture conditions using either breast cancer 
cell lines and clinical samples (Figure 3.8). Various microwell dimensions and 
substrate surface treatments were explored, and preliminary characterization of the 
microwell surface chemistry was carried out. Culture preparation procedures, mainly 
the length of culture, pre-preparation steps and incubation conditions were optimized 
directly with clinical samples.  
 
One of the critical issues of cultures involving clusters or aggregates is the possibility 
of cell necrosis due to the inability of oxygen penetration into the depth of the 
aggregate (Hirschhaeuser et al. 2010). In this project, a reduction of the proportion of 
Small CK+/CD45- cells beyond Day 14 was observed for most samples (70%, n=10) 
(Figure 3.4C). According to prior reports on hepatocyte spheroid cultures, the 
maximum threshold of spheroid diameter to maintain viability is ~100–150 μm 
(Curcio et al. 2007). The clusters obtained with the microwell assay described in this 
project mostly ranged within 30-100 μm (see Figure 3.13), hence cell necrosis due to 
lack of oxygen penetration might not be a dominant factor. However, it is possible 
that this phenomenon will be observable in more proliferative cultures generating 
larger or tighter clusters.  
 
On the other hand, induction of EMT by hypoxia via Notch signaling has been 
suggested by various findings (Sahlgren et al. 2008, Chen et al. 2010). qRT-PCR 
analysis of the microwell-based cultures similarly revealed significant gene 
expression increase of hypoxia-inducible factor 1 (HIF-1) and SNAIL-1, both of 
which are downstream components of the Notch pathway (see Figure 4.10A). Hence 
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reduction of CK+/CD45- cell portion could be due to induction of EMT. 
 
Ki-67 is a marker that closely correlates with proliferation (Urruticoechea et al. 2005). 
In this study, proportion of Ki67+/CD45- cells increased with culture, being highest at 
Day 14 (27.7%). As the cultures were subsequently harvested for other downstream 
analysis (including further proliferation as spheroids), it is desirable to select a time 
point where the cultures were most proliferative. 
 
The time-point with the highest Ki-67+ cell portion coincides with the time point with 
highest CK+/CD45- proportion. Since the current consensus defines CTCs as 
nucleated cells that express epithelial markers (e.g. Cytokeratin (CK)), maximum 
CK+ cell portion was used as a gauge to determine the time point with the highest 
amount of putative CTCs in culture. It is noteworthy to mention that this definition is 
now known to be inadequate for cancer cell identification, and hence might not reflect 
the time point with the highest amount of total CTCs (epithelial or mesenchymal). 
 
After optimization, 10 ml of clinical blood sample were cultured in four 60 mm non-
coated patterned dishes comprising of ~187.5 µm microwells in inner diameter to 
culture for all subsequent samples. Cultures were maintained under hypoxia to 
establish multilayered clusters comprising of CK+/CD45- putative CTCs, and 




Figure 3.8 Schematics of the optimization procedures. Either breast cancer cell 
lines or clinical samples were utilized when applicable. 
 
3.2 Overview of resultant cultures of clinical samples 
To visualize the cross section of microwells, PDMS replicas were produced. PDMS 
was coated and lifted off from the patterned dish (Figure 3.9), sliced and sectioned 
vertically (y-direction). PDMS is first mixed thoroughly with solvent at a 10:1 ratio 
(Sylgard 184, Dow Corning, USA), degassed in a mini-vacuum desiccator 
(Scienceware, Pequannock, NJ) for an hour, poured onto a patterned dish and cured at 
80 degrees Celsius (ºC) for another hour. The cured PDMS was then demolded from 





Figure 3.9 Fabrication of microwell assay via laser ablation. (A) Scanning electron 
microscope image illustrating the packed array of microwells for maximizing space. 
Scale bar is 100 μm. (B) Types of polystyrene substrates which can be patterned with 
microwells using the laser ablation technique. (C) Cross section of a PDMS replica 
demolded from a patterned dish.  
 
60 mm dishes with ellipsoidal microwells of ~225 μm x 145 μm x 150 μm dimensions 
(length x breadth x depth) were used for all subsequent cultures of clinical samples 
(Figure 3.10A-D). 
 
Using the optimized conditions as previously discussed, cultures comprising of 
putative CTCs were obtained from clinical samples from various breast cancer 
cohorts, and compared against samples from healthy volunteers. Observation of the 
cultures at Day 8 shows either the formation of single cell monolayers or only cell 
debris. Cultures might be expanded to form either multilayered clusters (for positive 
samples; 100s of cells per cluster) or be reduced to cellular debris (for negative patient 




Figure 3.10 Workflow for culture of clinical samples. (A-D) 60mm non coated 
dishes were patterned with an array of closely arranged microwells with estimated 
dimensions 225 μm x 145 μm x 150 μm. (E) Nucleated cells were seeded at Day 0 
and cultured. Either cell monolayers or debris could be observed by Day 8 of culture. 
Positive samples proliferated to form multilayered clusters, while negative samples 
were reduced to cell debris or retained only a monolayer of residual blood cells.  
 
To characterize the resultant cultures, Day 14 samples were harvested and subjected 





Figure 3.11 Schematic illustrating the series of downstream experiments done on 
cells obtained from established putative CTC cultures.  Cells were sorted manually 
for PAP stain with microfluidics to provide a better contrast of Large and Small cells 
in culture, while the rest were processed without pre-sorting and selectively analyzed. 
For samples which were not sorted, only Small (≤25 µm) cells with a single round 
nucleus displaying high N/C ratio were considered for analysis. 
 
3.2.1 Cell viability 
Day 14 positive cultures were harvested and stained with propidium iodide (PI) to 
determine the proportion of cells that were viable. Most cells (87.5 ± 8.9%, Figure 
3.12A) were PI
-
, suggesting that they were not apoptotic. On the other hand, viability 
was markedly decreased in negative cultures (56.6 ± 6.2%). To further verify the 
proportion of cells that might be viable but undergoing senescence, cultures were 
stained for SA -gal at pH 6 to screen for the proportion of senescent cells. It is 
determined that the majority of the culture was not senescent (90.1% were negative 
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Figure 3.12 Determination of the proportion of apoptotic or senescent cells in 
established putative CTC cultures. (A) Graphical representation of the proportion 
of cultured cells stained with PI dye to determine viability. Most cells were not 
apoptotic (87.5%). All error bars represent standard deviation (SD) of triplicates. 
Single asterisk indicates P < 0.01. (B) Representative images of cells stained with SA 
-gal. MCF-7 cells stained without pH adjustment served as a positive control for the 
antibody, while those stained at pH6 served as a negative control. Day 14 cultured 
cells stained at pH 6 demonstrate low percentage of - gal positive cells (9.9%). Scale 
bar, 20 μm. 
 
3.2.2 Size heterogeneity of clusters and individual cells 
The size of clusters obtained from a single sample varies, typically ranging from 30-
100 μm (Figure 3.13A). However, the range of heterogeneity for cultures across 
different dishes for the same sample should be the same, assuming the sample is 
resuspended homogeneously and seeded evenly across the dish.  
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Cultured cells could be harvested and separated into two distinct populations of 
different cell sizes, via size-based sorting with a microfluidic device (Khoo et al. 
2014). Measurements of the average cell diameter revealed a Small cell population of 
≤25 µm, while the larger cells were >25 µm (Figure 3.13B). The size range of the 
cultured Small cells were smaller (Median: 13.2 ± 1.2 µm) than the CK+/CD45- cells 
detected on Day 0 nucleated cell spots of corresponding samples (Median: 16.3 ± 3.9 
µm). Sorted cultured cells processed with Papanicolaou (PAP) stain revealed different 
morphology between the two sub-populations by size. Small cells exhibited strongly 
stained nuclei and high nuclear/cytoplasmic (N/C) ratio, which resembled malignant-
like features. Larger cells had relatively lightly stained nuclei with low N/C ratio 
(Figure 3.13C). These Large cells were also detected in a majority of cultures from 
healthy samples (76.5%, n=17) (Table 3.1) with no multilayered cluster formation 
(Figure 3.13D). As observed from their morphology, these Large cells were probably 
non-malignant cell types. Since the significance for the presence of Large cells is 
currently unclear, further evaluation (quantification of Large cell counts per sample), 
as well as correlation of the presence of Large cells with various factors (e.g. 




Table 3.1 Demographics for healthy volunteers (n=17). C = Chinese; M = Malay; I 
= Indian; O = Others; Y: Positive. N: Negative.  
No Race Age Multilayered cluster With Large cells 
1 I 26 N Y 
2 C 31 N Y 
3 C 28 N Y 
4 C 24 N N 
5 C 25 N Y 
6 C 25 N Y 
7 C 40 N Y 
8 M 25 N Y 
9 C 36 N Y 
10 I 36 N Y 
11 C 30 N N 
12 O 67 N Y 
13 C 26 N Y 
14 C 27 N Y 
15 C 28 N N 
16 I 27 N Y 





Figure 3.13 Cultures obtained from clinical samples vary from those generated 
with healthy blood. (A) Box plot demonstrating range of average diameter for 
resultant clusters within microwells. (B) Day 14 cultures consist of two distinct cell 
populations by size (Small cells: ≤25 µm, Large cells: >25 µm). Single asterisk 
indicates P <0.01. (C) Representative images of sorted cultures stained with 
Papanicolaou (PAP) dyes, highlighting their differences in morphology. Cultures from 
positive samples (patient) generated two distinct populations by size (Large and Small 
cells), while those from negative samples (healthy) led to cell debris or monolayer of 
residual blood cells. Scale bar is 10 μm. (D) 17 samples were obtained from healthy 
volunteers. Bar charts depicted the proportion of healthy samples displaying clusters, 
and if Large cells (>25 µm, possibly residual blood cells) were present. Cultures of 
healthy samples did not generate clusters (N), but Large cells were observed in some 
of these cultures (Y).  
 
To determine the identity of the Large cells, antibodies for several leukocyte and CTC 
associated markers were selected (Tables 2.1-2.2) to screen the cultures. Staining of 
the clusters in situ revealed that the larger cells were CD18+/CD68+ (leukocyte and 
macrophage markers respectively) (Figure 3.14A). Larger cells outside the 
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microwells were also CD18+/CD68+. Incubation with immunoglobulin G (IgG) -
coated 1 µm fluorescein-labeled polystyrene microbeads overnight showed that the 
Large cells had the phagocytic capability to ingest microbeads (Figure 3.14B), 
confirming that these Large cells were likely to be macrophages.  
 
Macrophages had been previously detected from blood via microfiltration, and were 
believed to potentially promote CTC dissemination and subsequent metastasis 
(Adams et al. 2014). Immunostaining of cells revealed that the CD68+ cells were also 
often positive for CK (Figure 3.14C), likely due to the expression of Fc receptors. 
Expression of epithelial markers is also common on activated leukocytes (Jung et al. 
1998, Kowalewska et al. 2006) (see Section 1.4). Time-lapse imaging of cultures 
showed that the Large macrophage-like cells appeared after 10 days in culture 
(Figure 3.14D).  
 




 cells under different culture conditions (H+W-, H-
W+ and H+W+) (Figure 3.14E-F) were investigated. It was observed that the cells 
derived from cultures maintained under H+W-, H-W+ were mostly CD18+/CD68+, 
while the majority of cells maintained under H+W+ conditions are CD18-/CD68- 









Figure 3.14 Phenotyping Large cells of cultures from clinical samples. (A) 
Immunostaining of cultures in situ for leukocyte (CD18) and macrophage (CD68) 
markers. Primary antibodies were counterstained with Alexa Fluor 488 secondary 
antibodies. Scale bar is 100 m. (B) Bright-field image demonstrating result of a 
phagocytic assay using 1 m polystyrene microbeads. Cells which took up the 
fluorescein-labeled microbeads displayed green fluorescence in the cytoplasmic 
regions (marked by white arrows), suggesting that they were macrophages. Scale bar 
is 50 m. (C) Immunostaining of cells with pan-CK-FITC, CD68-Alexa Fluor 546 
antibodies. CK+/CD68+ cells were detected in culture. Scale bar is 20 m. (D) Time-
lapse imaging of cultures demonstrated the appearance of large macrophage-like cells 
after Day 10 of culture. (E) Representative bar chart demonstrating proportion of 
unstained (CD68-CD18-) cells. All error bars represent standard deviation (SD) of 
triplicate cultures from different samples. (F) Characterization for the proportion of 
CD18+/CD68+ cells in cultures maintained under different culture conditions (H+W-, 
H-W+ and H+W+). Macrophage-like cells were detected in cultures maintained under 
H+W-, H-W+, while the majority of cells detected from cultures maintained under 
H+W+ were CD18-/CD68-. Scale bar is 20 μm.  
 
3.2.2 Detection of residual blood cells  
To analyze the presence of other blood cells, cells were harvested at different time 
points in culture (Day 0, 8 and 14) and split into portions for screening with a vast 
panel of antibodies (Tables 2.1 and 2.2) corresponding to haematopoietic precursors, 
endothelial markers, leukocyte markers, MSC, MSC-derived cell types and various 
other blood cell types. Screening with CD34 (haematopoietic precursor), CD45 and 
CD18 (leukocyte markers) demonstrated the progressive removal of blood cells over 
time (Figure 3.15A-B). CD34+ cells were completely absent after 14 days in culture, 







Figure 3.15 Immunostaining of cultures at different time points with antibodies 
targeting haematopoietic precursors and leukocytes. (A) Antibodies target 
haematopoietic precursors (CD34) and leukocytes (CD45 and CD18). Cultures from 
different time points (Day 0, 8, 14) were processed, and MCF-7 cells were used as a 
negative control to validate antibody specificity. Day 0 samples provided cells for a 
positive control. Representative images of the minority population (< ~50%) were 
provided in the box at the bottom left corner of the main image. Scale bar is 20 μm. 
(B) Bar charts demonstrating the percentage of CD34, CD45 or CD18 stained cells 
obtained from samples at different time points. All error bars represent standard 





Further screening was done with antibodies targeting monocytes, macrophages and 
other blood components such as platelets, natural killer (NK) cells and endothelial 
cells (Figure 3.16-3.17). Monocytes (CD14+ and CD16+ cells) were absent from 
cultures at Day 8 and 14. Macrophages (Macrophage inhibiting factor (MIF+ and 
CD68+) were detected as a minority population (<50%) in Day 8 and 14 samples. 
Platelets (Thrombospodin-1+ and Von Willebrand factor (vWF)+) and endothelial 
cells (CD31+) were also undetected in most cells for all time points, with the 
exception of NK cells (CD56+) (~33±26%). Proportion of macrophages and NK cells 
vary across patient samples, and may likely reflect worsened disease prognosis 






Figure 3.16 Immunostaining of cultures at different time points with antibodies 
targeting (A) monocytes, (B) macrophages.  Antibodies targeting monocytes (CD14 
and CD16) and macrophages (MIF) were utilized. Samples from different time points 
(Day 0, 8, 14) were processed, and MCF-7 cells were used as a negative control to 
validate antibody specificity. Day 0 samples provided cells for a positive control. 
Representative images of the minority population (<50%) were provided in the box at 
the bottom left corner of the main image. Scale bar is 20 μm. (B) Bar charts 
demonstrating the percentage of CD68 or MIF stained cells obtained from samples at 
different time points. All error bars represent standard deviation (SD) of triplicate 








Figure 3.17 Immunostaining of cultures at different time points with antibodies 
targeting other blood components. Antibodies targeting other blood components 
including megakaryocytes or platelets (Thrombospondin-1 and vWF), NK cells 
(CD56) and endothelial cells (CD31) were utilized. Samples from different time 
points (Day 0, 8, 14) were processed, and MCF-7 cells were used as a negative 
control to validate antibody specificity. Day 0 samples provided cells for a positive 
control (C). Representative images of the minority population (<50%) were provided 
in the box at the bottom left corner of the main image. Scale bar is 20 μm. (B) Bar 
charts demonstrating the percentage of CD56 or CD31 stained cells obtained from 
samples at different time points. All error bars represent standard deviation (SD) of 
triplicate cultures from different samples. 
 
3.2.3 Amplification of CK+ cells in culture 
After validating the progressive removal of blood cells from culture (with the 
exception of NK cells and macrophages), the proportion of putative CTCs before and 
after culture were estimated by detection of pan-CK+/CD45-/Hoechst+ cells at 
different culture time points. Direct staining of clusters within microwells revealed a 
random distribution of large macrophage-like CK+ cells. Small CK+ cells (either 
brightly or faintly stained due to heterogeneous expression level of CK) were present 
adjacent to the periphery of CD45+ cells, while those in the core were typically CK-
/CD45- (Figure 3.18A inset). These double negative cells are likely to be putative 
CTCs with more mesenchymal-like expression. 
 
Cells were also harvested on Day 0, 8, 14 and 21and concentrated into cell spots for 
CK+ putative CTC enumeration. It is worthy to note that the determination of putative 
CTCs via CK staining only provides an underestimation of CTC counts, since CTCs 
may not express CK to an observable extent (Schilling et al. 2012).  
 
Cytospots were stained with antibodies targeting CK8, 18 and 19 (pan-CK) and CD45 
while counterstained with Hoechst dye. Enumeration of the CK+/CD45-/Hoechst 
Small cell count revealed a gradual increase of the percentage of putative CK+ CTCs 
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over time, usually peaking at Day 14 of culture (Figure 3.18A) (Median of CK+ cells 
corresponding to per ml of blood: Day 0 is 1; Day 8 is 12; Day 14 is 64; Day 21 is 42). 
The peak appearance of CK+ putative CTCs in Day 14 samples (37.5% to 94.6%) 
support the decision to characterize cultures after two weeks in culture. Thus, 
subsequent downstream analyses were carried out with cultures up to 2 weeks culture.  
 
On the other hand, the proportion of putative CTCs after culture was found to 
correlate with the initial CTC counts at Day 0. Samples with >100 CK+ CTCs at Day 
0 generally lead to cultures with a higher CK+ CTC count at Day 14 of culture (5/6, 
83.3%) (Table 5.3). Interestingly, some of the samples with no detectable CTC 
fraction at Day 0 were later detected with CK+ putative CTCs after culture. Decrease 
in CK+ putative CTCs after Day 14 could be either due to cell death or an initiation of 
EMT, which reduces epithelial marker (e.g. cytokeratin) expression.  
 
The gene expression of CK18 in cultures were specifically determined by qRT-PCR, 
and compared to that of epithelial (MCF-7) and mesenchymal (MDA-MB-231) breast 
cancer cell lines (Figure 3.18B). Loss of CK18 has been reported to correlate with the 
onset of EMT, which promotes tumor progression via cell migration (Fortier et al. 
2013). It was apparent that the cultures had intermediate expression of CK18 after a 
week in culture, which was then also reduced at Day 14. This supports the finding that 




Figure 3.18 Characterizing putative CTCs (Small CK+ cells) in culture. (A)  Box 
plot illustrating range of putative CTCs (CK+/CD45-/Hoechst+) corresponding to per 
ml of blood, for cultures harvested at various time points. Image of cluster stained 
with pan-CK-FITC, CD45-APC and Hoechst is provided (inset; Scale bar is 50 μm). 
Single asterisk indicates P <0.01. (B) Ratio of CK18 gene expression of Day 8 and 14 
cultures, as well as MDA-MB-231 cell line, in contrast (normalized) to that of MCF-7 
cell line. Day 0 samples were not analyzed due to insufficient CTC counts. 
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To eradicate the possibility that CK+/CD45-/Hoechst+ cells could be MSC or MSC-
associated derivatives (since they also express epithelial cell markers), Day 14 
cultures were harvested and stained for a range of MSC (CD90) and MSC-associated 
(Aggrecan, FABP4, osteocalcin and Troponin T) specific markers (Table 2.1, Figure 
3.19). The MSC and MSC-associated cells were generally absent from the cultures. 
However, a portion of cells were positive for CD90, which is a marker for 
mesenchymal stem cells, but have also been recently reported to be expressed in 









Figure 3.19 Immunostaining of cultures at different time points with antibodies 
targeting MSCs or MSC derivatives. Samples from different time points (Day 0, 8, 
14) were processed, and MSCs and MCF-7 cells were used as positive and negative 
controls respectively to validate antibody specificity. Representative images of the 
minority population (<50%) were provided in the box at the bottom left corner of the 
main image. Scale bar is 20 μm. (B) Bar charts demonstrating the percentage of 
FABP4, osteocalcin or CD90 stained cells obtained from samples at different time 
points. All error bars represent standard deviation (SD) of triplicate cultures from 
different samples. 
 
3.3 Chapter summary  
A culture protocol for primary cancer cells using microwells was designed and 
optimized. Microwells of ~187.5 µm in inner diameter were generated on uncoated 
dishes with a laser ablation technique at 10% speed and 50% laser power. Length of 
culture was established to be Day 14, when most samples were found to have the 
highest CK+/CD45- and Ki67+ cell proportions. Nucleated cells were obtained with 
RBC lysis buffer processing, and supplemented DMEM is used for all cultures for 
consistency. A combination of hypoxia and the presence of microwells were required 
for the establishment of multilayered clusters. The minimum volume of patient blood 
required to correctly evaluate a sample was found to be ~2.3 ml of blood per patterned 
60 mm dish.  
 
Actual clinical samples were used to validate the protocol. It was found that cultures 
might be expanded to form either multilayered clusters (positive) or be reduced to 
cellular debris (negative) after two weeks. Majority of the cultured cells were not 
senescent. Cultures consist of a heterogeneous range of cells, including double 
negative cells which are likely to be putative CTCs with more mesenchymal-like 
expression. 
 
Sorted cultured cells revealed small cells which exhibited malignant-like features with 
strongly stained nuclei and high nuclear/cytoplasmic (N/C) ratio, as well as larger 
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cells with relatively lightly stained nuclei with low N/C ratio. Phagocytosis assay and 
immunolabeling confirmed that these large cells were macrophages. Apart from 
macrophages, NK cells were also presented in the residual leukocyte portion. 
Proportion of macrophages and NK cells vary across patient samples, and may likely 
reflect worsened disease prognosis (Adams et al. 2014). Haematopoietic precursors, 
endothelial cells, MSC, MSC-derived cell types and various other blood cell types 
were not detected.  
 
Proportion of putative CTCs after culture was found to correlate with the initial CTC 
counts at Day 0. However, some of the samples with no detectable CTC fraction at 
Day 0 were also later detected with CK+ putative CTCs after culture. 
 
 






Chapter 4: Characterization of Cultured CTCs  
4.1 Detection of cultured CTCs with genetic alterations 
4.1.1 DNA FISH 
Enumeration of putative CTCs in culture via detection of EpCAM+ or CK+ cells 
could only provide an underestimate of CTC counts. The epithelial markers used for 
identifying CTCs were also not specific to carcinoma cells. Hence, detection of cells 
overexpressing cancer-specific genes might provide a more relevant estimate of the 
actual CTC counts.  
 
Cancer cells are commonly accumulated with various genetic alterations, possibly due 
to their genetic instability which generates a vast heterogeneity within the tumor. 
CTCs are believed to be conferred with a similar degree of genetic variation, as they 
are shed directly from either primary and/or secondary tumors.  
 
To validate this, Day 14 cultures were harvested and concentrated as cell spots for 
DNA FISH as described in Materials and Methods. The six genes selected for 
screening (FGFR1, MYC, CCND1, HER2, TOP2A and ZNF217; Table 2.4) are 
commonly altered in breast cancer. They constitute about 44% of driver mutations in 
combination (Davies et al. 2002, Magbanua et al. 2012), which may be detected as a 
copy number increase or presence of amplicons.  
 
Probes corresponding to these six genes were first hybridized to cell spots 
individually (Figure 4.1A). 10 samples at Day 14 of culture were harvested and 
sorted into portions for hybridization to each Spectrum Orange-labeled probe. 
Putative cancer cells with copy number increase in cancer genes were defined as those 
expressing ≥3 red signals. Amplification of the breast cancer associated genes was not 
observed in WBCs (1 or 2 red signals for haploid and diploid cells respectively) 
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(Figure 4.1B). The gene expression amongst cultured cells were heterogeneous and 
4/10 samples had copy number increase in 1 or more genes for at least 40% (~90
th
 






Figure 4.1 DNA FISH of cultured cells and controls (1 probe to 1 sample). (A) 
Representative images of cultured putative CTCs hybridized with single DNA probes 
corresponding to genes commonly altered in breast cancer (FGFR1, MYC, CCND1, 
HER2, TOP2A and ZNF217). Scale bar is 20 μm. (B) Freshly lysed blood sample, 
consisting mostly of WBCs, was used as a negative control (right) to validate the 
specificity of probes. WBCs do not demonstrate copy number increase for the probes 
targeting breast cancer associated genes (mostly with one or a pair of faint red signals), 





Figure 4.2 Quantification of the percentage of cells with ≥3 red signals after DNA 
FISH (1 probe to 1 sample). Each chart corresponds to analysis from a single sample. 
Proportion of cultured cells with increase in copy number of cancer genes vary, with 
some samples having more than 40% (90
th




To determine the total percentage of cells with copy number increase in cancer genes, 
another 27 samples were harvested and hybridized individually to all six probes, on 
top of a CEN17 probe (Figure 4.3A). Increase in copy number of CEN17 indicates 
cell polyploidy, which is associated with cancer progression. Due to the combination 
of the six spectrum-orange labeled probes, cells with copy number increase in target 
genes were defined as cells expressing ≥13 red signals. Cells with copy number 
increase in CEN17 were defined as those with ≥3 green signals.  
 
Not all samples were found to have copy number increase in CEN17 (92.6%, n=27; 
Range: 10.3-85.7%, Mean: 46.2%), an observation which could be attributed to the 
heterogeneity of the samples (Figure 4.3B). Two samples did not express copy 
number increase in both CEN17 and target genes. This was expected, since the target 
genes only constitute about 44% of driver mutations in combination (Davies et al. 
2002, Magbanua et al. 2012). It was observed that some samples expressing copy 
number increase in CEN17 might also not be detected with copy number increase in 
target genes (85.2%, n=27; Range: 7.1-80%, Mean: 35.9%). There appeared to be a 
lack of association between copy number increase of CEN17 and cancer-associated 
genes, which was similar to that reported in other studies (Lehmann-Che et al. 2011). 
Detection of copy number increase in the target genes (constituting ~ 44% of driver 
mutations in combination) represented the likely presence of a cancer cell, thus these 











Figure 4.3 Combined DNA FISH (6 probes to 1 sample) for cultured cells. (A) 
Representative merged images (DAPI, spectrum green, spectrum orange) of cells 
hybridized with all six target probes (FGFR1, MYC, CCND1, HER2, TOP2A and 
ZNF217, all red) per sample. Cells with copy number increase in target genes were 
defined as cells expressing ≥13 red signals. Cells with copy number increase in 
CEN17 were defined as those with ≥3 green signals. Scale bar, 20 μm. (B) DNA FISH 
for Day 4 culture (which consisted mainly of blood cells) and Day 14 culture. Boxed 
images (marked in white) provided examples of a distinct minority phenotype (<50%) 
from the majority of cells. Scale bar, 20 μm. (C) Bar charts demonstrating the 
percentage of cells of Small cells with target gene or CEN17 copy number increase in 
27 cultured samples. Each chart corresponds to analysis from a single sample. The 
combined prevalence of copy number increase in the six target genes correspond to 
~44% of all breast cancers. Each bar refers to a respective sample as numbered (x-
axis).  
 
4.2 EMT phenotypes 
EpCAM+ cancer cells are not associated at all with 30% of tumor subtypes (Went et 
al. 2004), while CK+ cancer cells may not be observed in certain CTC populations 
(Fehm et al. 2002). Similar phenotypic changes in cell lines obtained from 
disseminated carcinoma cells (DTCs) from the bone marrow were also often observed 
(Willipinski-Stapelfeldt et al. 2005), supporting that EpCAM- and CK- phenotypes 
could also be detected with cultured CTCs. 
 
It is believed that CTCs were as heterogeneous as the tumor in vivo, as reported by 
others for breast (Kallergi et al. 2011), prostate (Armstrong et al. 2011, Chen et al. 
2013) and head and neck cancer (Balasubramanian et al. 2012). CTC heterogeneity 
could be attributed to a partial or complete reversible process of EMT (Thiery and 
Lim 2013), and might even exhibit one or more phenotypes in their entire transit time 
within the peripheral circulation (Labelle et al. 2011). EMT phenotypes are of great 
interest as the EMT process has been closely linked to stem cell-like properties 
(Wicha 2014) and invasive potential of cells (Tam and Weinberg 2013).   
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4.2.1 Pooled sample analysis with qRT-PCR 
In this project, EMT phenotypes were first investigated via qRT-PCR of pooled 
samples harvested at different culture time points (Day 8 and 14). Several epithelial 
(EPCAM and CDH1) and mesenchymal (Vimentin) associated genes, along with two 
breast cancer markers associated with stemness properties (CD44 and CD24) were 
investigated. The expression profiles of cultured samples were normalized to that of 
MCF-7 cells (Figure 4.4). There was a general decrease in the expression of epithelial 
markers and an overall increase of mesenchymal genes in cultured samples. The 
changes in phenotypic expression appeared to stabilize over time as the culture 
develops. However, these data were inconclusive due to the presence of blood cells in 




Figure 4.4 Gene expression profiles of EMT associated genes via qRT-PCR. (A) 
EPCAM, (B) Vimentin and (C) CDH1, as well as stemness associated genes (D) 
CD24 and (E) CD44 were obtained and normalized to that of MCF-7 cells. All error 
bars represent standard deviation (SD) of triplicates. 
 
4.2.2 Single cell characterization with immunostaining 
To validate this trend more specifically, single cell characterization were carried out 
on the Small cell portion of samples before and after culture, using antibodies or 
probes targeting known EMT markers. A list of markers associated with epithelial (E) 
and mesenchymal (M) expression (Epithelial: E-cadherin, CK5, CK7, CK18, CK19 
and EpCAM; Mesenchymal: Vimentin and Fascin) (Akalay et al. 2013) were selected 
for immunochemical screening of the Small cell cohort (Table 2.2, Figure 4.5). MCF-
7 and MDA-MB-231 cell lines were used as positive controls, representing epithelial 
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and mesenchymal carcinomas respectively. Day 0 cultures (freshly RBC lysed blood 
sample) act as a negative control for most markers (except vimentin staining, where 
MCF-7 acts as the negative control) as they consist mostly of leukocytes. EMT status 
of putative CTCs at Day 14 was heterogeneous, with a majority of cells positive for 
Vimentin, while negative for E-cadhein and EpCAM. Loss of E-cadherin was 
important as this had been often associated with gain of metastatic traits (Onder et al. 
2008). Staining of cultures from Day 8 and 14 time points suggested that the cultured 
cells became increasingly more mesenchymal-like. Individual CK immunolabelling 
demonstrated that cultured cells had a higher expression of CK5 (associated with 
mesenchymal phenotypes) as compared with CK7, CK18 and CK19 (associated with 
epithelial phenotypes). The expressions of these cytokeratins in cultured cells 
appeared to be at intermediate levels in contrast to that in full blown epithelial (MCF-








Figure 4.5 Immunostaining of epithelial and mesenchymal markers for Day 14 
cultures. Boxed images (marked in white) provided examples of a distinct minority 
phenotype from the majority of cells (<50%). Cells generally demonstrated increased 
expression of mesenchymal markers (Vimentin and Fascin), and decreased expression 
of epithelial markers (EpCAM and E-cadherin). Individual cytokeratin staining (CK 5, 
7, 18 and 19) demonstrated that the cultured cells were more positive for CK5 and 7 
as compared to CK18 and 19. MCF-7 and MDA-MB-231 breast cancer cell lines were 
used as references for epithelial and mesenchymal carcinoma cell lines, respectively. 
Scale bar, 20 μm. 
 
4.2.3 RNA FISH 
To consider the proportion of cells transcribing EMT-associated genes but not 
translating them into proteins, RNA FISH was carried out to better determine the 
amount of epithelial-like (E) and mesenchymal-like (M) cells. Thirteen genes, 
including nine epithelial (E: CK7, 8, 18, 19, CDH1, TFF1, FOXA1, AGR2 and 
GATA3) and 4 mesenchymal (M: PTX3, SERPINE2, VIM, FASCIN) (Table 2.5) 
genes were targeted with probes from Affymetrix. E probes were labeled green 
(emission: 488 nm) and M probes were labeled red (emission: 550 nm). Due to the 
density of E probes (9 probes per sample), cells expressing a high amount of epithelial 
associated genes would appear green, instead of having distinct green signals (Yu et al. 
2012). M cells displayed distinct red signals (Figure 4.6A). Cell lines (MCF-7 and 
MDA-MB-231) were utilized as epithelial and mesenchymal cell line references 
respectively (Figure 4.6B).  
 
RNA FISH processing of 10 samples from individual patients revealed variation of 
EMT phenotypes across cultures. The 10 patients were previously determined by the 
clinician for their oestrogen receptor (ER), progesterone receptor (PR) and HER2 
status. In a further attempt to evaluate any correlations between the EMT statuses of 
samples with patient’s ER/PR/HER2 status, EMT status data were classified 
according to patients of respective ER/PR/HER2 status combination. Cluster 
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formation appeared to demonstrate no correlation to ER, PR or HER2 status (Figure 
4.6C). However, ER positive/PR positive/HER2 negative samples (PPN) (n=8) did 
contain a higher proportion of E and EM (intermediate) cell types, even though one 
sample appeared to be fully M. Overall, the genomic and proteomic expression of 
EMT markers were heterogeneous, which was consistent with other reports on CTCs 














Figure 4.6 RNA FISH with probes targeting EMT markers. (A) Epithelial genes 
were hybridized to green (488)-labeled probes targeting CK7, 8, 18, 19, CDH1, TFF1, 
FOXA1, AGR2 and GATA, while mesenchymal genes were hybridized to red (550)-
labeled probes targeting PTX3, SERPINE2, Vimentin and Fascin. E: Epithelial-like, 
M: Mesenchymal-like, EM: Epithelial-Mesenchymal-like. Scale bar, 20 μm. (B) RNA 
FISH of the same probe combination with control cell lines MCF-7 (epithelial) and 
MDA-MB-231 (mesenchymal). MCF-7 cells were labeled green and MDA-MB-231 
cells demonstrated red signals respectively. Scale bar, 20 μm. (C) Proportion of cells 
in 10 samples with E, M or EM status. Cells were considered as E if the cytoplasm 
display green signal with few red signals or if the green: red signal ratio is >2. Cells 
were classified as M if green: red signal ratio is <2. The rest were classified under EM. 
EMT phenotypes were heterogeneous across samples with different ER, PR and 
HER2 status. PPN: ER positive/PR positive/HER2 negative samples, NNN: ER 
negative/PR negative/HER2 negative, NNP: ER negative/PR negative/HER2 positive 
status. Each bar corresponds to a respective sample as numbered. X axis indicates the 
ER, PR and HER2 status of the patient.   
 
4.2.4 Cancer stem cells (CSCs) 
CSCs belong to a rare subpopulation of stem-like carcinoma cells (Al-Hajj et al. 2003, 
Ho et al. 2007), usually isolated from tumors via affinity binding techniques (Eramo 
et al. 2008, Li et al. 2009). They were first observed in the 1960s, from the generation 
of teratomas from primodial germ cells (Stevens 1964). They have now been detected 
in various cancer types (including blood cancers) (Lapidot et al. 1994, Bui and Reiter 
1998, Singh et al. 2003), and were known to express intermediate EMT phenotypes 
(Mani et al. 2008, Thiery and Lim 2013, Wicha 2014).  
 
EMT is a process that generates a spectrum of cell phenotypes, and is hypothesized to 
contribute to the generation of CSC sub-population (Brabletz 2012). In vitro CSC 
cultures obtained from tumors were established typically with non-adhesive substrates 
(Al-Hajj et al. 2003, Tosoni et al. 2012) and hypoxia (Soeda et al. 2009, Lu et al. 
2010), which are conditions similar to that used in the CTC method described in this 
project. In addition, CSC-like cells were also reported to be present amongst the 
enriched CTC populations (Kasimir-Bauer et al. 2012, Hou et al. 2013). Hence it is 
assumed that CSCs might be amplified in the CTC culture. 
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To demonstrate this, markers used to identify breast CSCs (CD44+/CD24-) (Al-Hajj 
et al. 2003) were utilized to investigate their expression in cultured cells. Under the 
absence of either microwells (W) or hypoxia (H), relative proportion of 
CD44+/CD24- (phenotype of CSCs) was reduced as compared to cells cultured under 
H+W+ (Figure 4.7; W-H+ to W+H- to W+H+ is 0.62 to 0.42 to 1). No CD44+/CD24- 




Figure 4.7 Proportion of putative breast CSCs (CD44+/CD24-) in cultures. (A) 
Representative images of immunostained cells derived from cultures maintained 
under different conditions. Scale bar, 20 μm. (B) Bar graphs illustrating the 
quantitative proportions of CD44+/CD24-, CD44-/CD24+ or CD44+/CD24+. 
CD44+/CD24+ cells are those at intermediate EMT stages. All error bars represent 
standard deviation (SD) of triplicates. Asterisks indicate significance of P ≤ 0.05. 
 
On the other hand, several markers of embryonic stem cells (SOX2, Rex1, Nanog and 
Oct4) (Kim et al. 2008) were screened to determine presence of cells expressing 
markers corresponding to embryonic stem cells (ESCs). Intriguingly, only Rex1 was 
detected in both Day 8 and Day 14 samples (Day 14: 78.5 ± 17% of positive cells; 
Figure 4.8). Rex1 has been reported to be expressed in murine teracarcinoma stem 
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cells (Hosler et al. 1993), and could also suggest the presence of CSCs in these 
cultures. SOX2 was detected in Day 8 cultures, but not in Day 14. This 
downregulation of SOX2 could have contributed to the cell growth inhibition 
observed at later culture time points (see Section 4.3) (Herreros-Villanueva, 2013 
#271). 
 
In vitro cultures of spheroids are often used to select and grow tumorigenic cancer 
cells (Liu et al. 2012). It was found that the cultured samples could also be passaged 
at Day 14 and transferred into 3D Geltrex® or ultra-low adhesive dishes to form 
spheroids (Figure 4.9), supporting that tumorigenic cells were present in the cultures 













Figure 4.8 Immunostaining of cultured cells from different sample time points 
with antibodies targeting ESC-associated markers. (A) Cells were positive for an 
ESC marker (Rex1) at Day 14 but not for the others (SOX2, Nanog and Oct4). Boxed 
images (marked in white) provide examples of a distinct minority phenotype from the 
majority of cells (<50%). Representative images of the positive and negative controls 
for the antibodies are provided in the 2
nd
 last and last columns using ESC and blood 
cells from Day 0 lysed blood respectively. Scale bar, 20 μm. (B) Bar charts 
demonstrating the percentage of SOX2 or REX1 stained cells obtained from samples 
at different time points. All error bars represent standard deviation (SD) of triplicate 




Figure 4.9 Formation of spheroids in 3D Geltrex or low adhesive substrates. (A) 
Day 14 cultures can be transferred into 3D Geltrex® for further expansion into 
spheroids. (Top) Spheroids stained for F-actin and Hoechst. (Bottom) Some cells were 
observed to be migrating out of the spheroids into the surrounding matrix. Scale bar is 
100 μm. (B) Cultures could also be transferred into ultra-low adhesive dishes for 
propagation as spheroids over 10 days, and can withstand passages for at least 4 to 6 
times. Resultant spheroids were stained for Hoechst, pan-CK and CD45 antibodies. 
Cells were mostly Hoechst+/pan-CK+/CD45-. 2 panels (left, right) displaying 
representative spheroids were shown here. Scale bar is 100 μm. 
     
4.3 Functional characteristics and mechanisms of cultured CTCs 
The functional characteristics of CTCs are still an unchartered territory. A key 
question facing CTC culture protocols would be regarding the mechanisms of 
proliferation. A hypothesis could be that the induction of EMT triggers the formation 
of CSC (sub-population of CTCs) (Brabletz 2012), which then proliferate to form 
clusters.  
 
However, the exact signals of EMT are often unclear. One possibility is the induction 
of EMT by hypoxia via Notch signaling, as suggested by previous findings (Sahlgren 
et al. 2008). qRT-PCR analysis of cultures revealed significant gene expression 
increase of hypoxia-inducible factor 1 (HIF-1) and SNAIL-1, both of which are 
downstream components of the Notch pathway (Figure 4.10A). SNAIL-1 is also 
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termed as the ‘survival factor’ that leads to protective traits and induce partial G1/S 
cell-cycle arrest (Barrallo-Gimeno and Nieto 2005). A similar observation has been 
detected in the CSC subpopulations (Ho et al. 2007), with the majority of cells being 
reported in the G0 quiescent state. Interestingly, cell cycle analysis with PI staining 
seemed to suggest the presence of a similar cell cycle arrest (enhanced S phase) in 
flow cytometry analysis of Day 14 cultured samples (Figure 4.10B).  
 
Other regulatory systems such as the claudin or Wnt pathways (Visvader 2011) might 
also be working in parallel to generate the unique heterogeneity of CTCs. Western 
blot analysis supports previous findings (that most cultured cells approach a more 
mesenchymal-like phenotype)(Figure 4.5, Figure 4.7), as suggested by the 
downregulation (EpCAM, E-cadherin and CD24) as well as up-regulation (ZEB-1, c-
kit, vimentin, CD44 and SNAIL-1) of epithelial and mesenchymal associated proteins 
respectively (Figure 4.10C). However, western blot analysis is not a favored mode of 
characterization for CTC samples, as it usually requires large amounts of sample input 
and does not provide quantitative analysis. 
 
There are few indicators to evaluate cancer cells for their metastatic potential, and 
most are of low efficiency. Xenografts are the most direct way to confirm tumorigenic 
properties, but the method is costly and success rate is often low (Baccelli et al. 2013). 
CTC xenograft experiments were not attempted at this point of time, because the 
cultures appeared to contain cells which mostly become arrested in the intermediate S 
phase, and might not be able to divide further (Figure 4.10B). Similar reduction of 
proliferative capability in the progeny as compared to the progenitors has been often 
reported in stem cells(Tosoni et al. 2012). Intriguingly for some samples, passage of 2 
weeks culture into fresh Geltrex® or non-adherent dishes appeared to trigger 
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proliferation again, forming spheroids (~50% of cultures tested, n=6) (Figure 4.9).  
 
 
Figure 4.10 Gene or protein expression analyses to suggest mechanisms for CTC 
proliferation. (A) Normalized Ct value correlating to gene expression of Small cell 
CTC culture cohort as compared to that of MCF-7 cell line. All error bars represent 
standard deviation (SD) of triplicates. Asterisks indicate a significance of p < 0.05. (B) 
Flow cytometry analysis of PI-stained Small cell culture cohort (Day 14), blood cells 
(Day 0 lysed sample) or polyploidy cancer cell line (MDA-MB-231). CTC cultures 
exhibited a distinct enlarged S-phase in contrast to freshly lysed blood samples at Day 
0. (C) Western blot analysis indicating up- or down- regulation of EMT associated 
proteins in contrast to expression of beta-actin. 
 
Potential invasiveness of cultures was explored with invadopodia assays. Results 
suggested that a proportion of cultured cells could lead to the degradation of matrix 
(Figure 4.11A), and the proportion of invasive cells vary across samples. Most 
degraded areas due to invadopodia or podosome formation were 'blotchy', while some 
gave rise to 'punctate' patterns. Some cultures contained cells which were more 
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migratory or were able to degrade the extracellular matrix more efficiently than others 
(Figure 4.11B-C). Cells which were more migratory generated a larger degraded 
matrix to cell area ratio.   
 
Invasiveness is often associated with higher migratory speeds (Christofori 2006). 
Filamentous (F)-actin polarization is crucial for physically inducing a cell’s migration 
(van Oudenaarden and Theriot 1999, Snapper et al. 2001). To determine the pattern of 
F-actin expression in CTCs, four cultures were stained with phallodin, and the 
resultant images were contrasted with those obtained with stained cancer cell lines 
(MCF-7 and MDA-MB-231) (Figure 4.11D). MDA-MB-231 formed distinct F-actin 
stress fibers, while MCF-7 cells displayed F-actin fibers of higher bundle density. 
Cultured CTCs appeared to demonstrate high expression of condensed F-actin within 
the perinuclear zone, which is an observation usually associated with exposure to 





Figure 4.11 Invasiveness and migratory aspects of cultured CTCs. (A) Proportion 
of cultured cells which led to matrix degradation. Each bar graph (numbered 1-4) 
represents an individual sample. All error bars represent standard deviation (SD) of 
data from cells in each individual sample. (B) Percentage of degraded matrix area to 
cell area. Each box chart (numbered 1-4) represents an individual sample. Some 
percentages were higher than 100% due to migration of cells which generated a wider 
degradation area with respect to cell size. Single asterisk indicates P <0.01. 
(C) Imaging of gelatin substrate (green)/TRITC-phallodin/DAPI stained cells. Scale 
bar is 100 μm. (D) Phallodin staining to reveal F-actin expression of cell lines (MCF-
7 and MDA-MB-231) and cultured CTCs respectively. Two representative images of 
each cell type were provided (top and bottom panels). White asterisk indicates cell 
displaying high expression of condensed F-actin within the perinuclear zone. Scale 
bar is 20 μm. 
 
4.4 Chapter summary 
Extensive screening of samples with a range of DNA FISH probes corresponding to ~ 
44% of driver mutations in combination confirmed the presence of copy number 
increase in these driver mutations and represented the likely presence of cancer cells. 
 
Preliminary western blot analysis suggested an adaptation of cells towards the 
mesenchymal phenotype. Further investigation with RNA FISH Affymetrix probes 
concludes that the genomic and proteomic expression of EMT markers were 
heterogeneous. This heterogeneity is validated by both pooled sample analysis with 
qRT-PCR and single cell characterization of EMT proteins with immunostaining. 
 
 
Immunostaining of embryonic stem cell markers demonstrated the expression of Rex1 
in the cultured samples, which suggest the presence of CSCs in these cultures. Under 
the absence of either microwells or hypoxia, relative proportion of CD44+/CD24- 
(phenotype of breast CSCs) was reduced as compared to cells cultured under 
normoxia or in non-tapered microwells. 
 
The pathways influencing proliferation of CTCs have not been investigated. qRT-PCR 
analysis of cultured CTCs suggested the role of the Notch pathway, due to increased  
 114 
HIF- -1 expressions. SNAIL-1 is also termed as the ‘survival factor’ 
that leads to protective traits and induce partial G1/S cell-cycle arrest (Barrallo-
Gimeno and Nieto 2005). Cell cycle arrest in Day 14 cultured samples were 
confirmed with PI staining under flow cytometry analysis.  
 
Despite undergoing cell cycle arrest, some samples could be induced to form 










Chapter 5 Clinical Utility of CTC cultures 
5.1 Sample cohort 
CTC counts have been reported to correlate negatively with patient survival 
(Cristofanilli et al. 2005, de Bono et al. 2008). Having optimized the culture 
conditions, it was determined if the presence of clusters is predictive of a patient’s 
survival or response to treatment. To date, 173 blood samples of 10 ml each from a 
total of 60 patients with clinically measurable tumors, classified under locally 
advanced (P2A/B and PCL cohorts) or metastatic (CTB cohort) breast cancer, were 
screened for this study. These samples were obtained at different time points (pre or 
post onset) of the current treatment regime. The demographic details of these patients 
are summarized in Table 5.1. Correlations between cluster formation and the 




Table 5.1 Demographic details of patients (n=60) with locally advanced or 
metastatic breast cancer. ILC = Invasive Lobular Carcinoma; IDC = Invasive Ductal 
Carcinoma; AJCC = American Joint Committee on Cancer; ER = Oestrogen receptor; 
PR = Progesterone receptor; HER2 = Human Epidermal Growth Factor Receptor 2; 
AC = Doxorubicin /Cyclophosphamide.  
Age (years) 
Median 47.5  
Range 33-78  
Race 
Chinese 38 63.3% 
Indian 5 8.3% 
Malay 11 18.3% 
Others 6 10% 
Histology 
IDC 49 81.7% 
ILC or IDC with lobular features 5 8.3% 
Others 6 10% 
tumor grade 
1 3 5% 
2 18 30% 
3 35 58.3% 
Not specified 4 6.7% 
Metastatic disease 
Yes 25 41.7% 
No 35 58.3% 
AJCC stage 
I 0 0% 
II 16 26.7% 
III 19 31.7% 
IV 25 41.7% 
ER status 
Negative 21 35% 
Positive 39 65% 
PR status 
Negative 18 30% 
Positive 42 70% 
HER2 status 
Negative 47 78.3% 
Positive 13 21.7% 
Treatment regimen 
AC 15 25% 
AC+Sunitinib 16 26.7% 
Paclitaxel/carboplatin/lapatinib 7 11.7% 
Others 22 36.7% 
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5.2 Evaluation and tabulating of results  
To examine possible correlations between cluster formation and patient prognosis, 
details of each individual sample were mapped and contrasted to the presence of 
cluster after 2 weeks culture (see Appendix Tables A1.1-1.4). Positive samples were 
marked as Y, while negative samples were marked N.  
 
5.2.1 Metastatic cohort (CTB)  
The refractory metastatic cohort consisted of 30 samples from 22 patients enrolled 
when they presented with progressive disease after their last treatment regimen, but 
before commencing with a new treatment regimen (chemotherapy, endocrine therapy 
or radiotherapy) (see Appendix Table A1.1). Of which, 73.3% of all samples formed 
clusters in culture, and more than half came from pre-treatment samples (14/22, 63.6% 
of samples). Of the 8 patients with samples provided at both pre-treatment and post-
treatment time points, 6 patients had positive pre-treatment samples, and 33.3% (2/6) 
of them had a negative post-treatment sample. These 2 patients either had radiological 
responsive or stable disease (p=0.308). For the other 4 patients, 50% (2/4) had early 
radiological progressive disease while one was not accessed. These suggest that 
cluster formation may correlate with poorer prognosis. 
 
To further verify this, a Kaplan–Meier survival analysis was performed on the 14 




Table 5.2 List of 14 post-treatment samples from patients with refractory cancer 
computed for survival statistics in Figure 5B. 
Sample ID Survived 
With early radiological 
progressive disease 
(within 3 months) 
OS 
(months) Cluster 
1 CTB 002 Y Y 28.41 N 
2 CTB 004 N Y 13.98 N 
3 CTB 005 N Y 8.81 Y 
4 CTB 006 N N 5.72 Y 
5 CTB 007 N Y 4.14 Y 
6 CTB 009 N Y 6.12 Y 
7 CTB 012 N Y 8.94 N 
8 CTB 014 N NA 16.54 Y 
9 CTB 015 N 
Radiological response after 
2 months 6.35 N 
10 CTB 016 Y N 16.97 N 
11 CTB 017 Y N 21.21 N 
12 CTB 019 N N 14.21 Y 
13 CTB 026 Y N 8.22 Y 




Graphical representation of the data confirmed that cluster formation correlated with 
shorter overall survival in patients (Figure 5.1). Patients providing samples that led to 
clusters experienced a mean survival period of 9.8 months (95% confidence interval 
(CI), 5.9-13.7), while patients who provided samples that did not lead to clusters had a 
longer mean survival period of 16.6 months (95% CI, 10.4-22.8; log rank p-value, 
0.087). Further Cox regression (investigation of multiple variables) or adjusted 
analyses (to other variables) were not carried out due to the small sample size. 
Although the results were not statistically significant (due to small sample size), these 






Figure 5.1 Graphical representation of the Kaplan–Meier survival analysis. 
Comparison of overall (cumulative) survival in refractory metastatic patients (CTB 
cohort) who provided samples at post treatment time points against cluster formation 
(n=14). Data is summarized in separated table (below). 
     
5.2.2 Locally advanced patients (PCL and P2A/B cohorts)  
The locally advanced cohort consisted of samples from two treatment regimes. In the 
PCL (Paclitaxel+carboplatin+lapatinib) treated cohort, 7 patients were enrolled and 28 
samples were obtained at either single or multiple time points (see Appendix Table 
A1.2). Of which, 78.6% of all samples formed clusters in culture, and cluster 
formation was also progressively reduced in samples obtained at later treatment time 
points (Pre-treatment and <3 weeks post-treatment: 100% (n=8); 6-9 weeks post-
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treatment: 75% (n=8); pre- or post- surgery: 63.6% (n=11); p<0.001).  
 
In the P2A/B cohorts (AC with or without intermittent sunitinib (sutent)), 31 patients 
were recruited and 115 samples were obtained at either single or multiple time points 
(see Appendix Table A1.3). Of which, 63.6% of all P2A samples and 61.7% of all 
P2B samples formed clusters in culture, and cluster formation was similarly reduced 
in samples of later treatment time points (Figure 5.2) (P2A: Pre-treatment – 90.9% 
(n=11); 2-3 weeks post-treatment: 80% (n=20); 6-11 weeks post-treatment: 47.1% 
(n=17); pre- or post- surgery: 0% (n=6); p<0.001 and P2B: Pre-treatment and post 
sutent pre AC – 83.3% (n=24); 2-3 weeks post-treatment: 72.2% (n=18); 6-11 weeks 
post-treatment: 28.6% (n=14); pre- or post- surgery: 0% (n=4); p<0.001). These 
findings further support the possibility that the potential of CTC cluster formation 
could be used as an early predictor of treatment response. 
 
Intriguingly, for the P2A cohort, 66.6% pre-treatment samples (n=3) which did not 
yield clusters came from patients with invasive lobular carcinoma (ILC). The other 
P2A/B samples (n=3; 2 from 2-3 weeks post-treatment, 1 from post-surgery) from 
patients with ILC also did not form clusters, with the exception of one post-treatment 
sample from the P2A cohort. These suggest that the current CTC culture conditions 
might not be able to promote growth of certain cancer subtypes.   
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Figure 5.2 Clinical correlation of cluster formation with patient survival. 
Treatment schedule for the patients (n=31) receiving Doxorubicin/cyclophosphamide 
(AC) (A) without or (B) with Sunitinib. Cluster formation is reduced during therapy 
cycles, reflecting response to chemotherapy for treatment efficacy. 
  
5.2.3 Cluster formation in early-stage cancer samples (CES cohort) 
From the metastatic and locally advanced cohorts, the overall cluster formation 
frequency was 66.5% (n=173). This is significantly higher than previously reported 
CTC culture techniques (Table 1.3). In fact, the culture protocol was able to identify 
putative CK+ CTCs (cluster formation) from samples with initial negligible amount 
of CK+ CTCs (Table 5.3).   
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Table 5.3 CK+ CTC cell count ml
-1
 of blood 
Sample no 
CK+ cell count ml
-1
 of blood Amplification  
Day 0 Day 14 (fold change) 
1 220 6912 31.4 
2 165 6451 39 
3 154 1578 10.2 
4 120 1901 15.8 
5 104 4506 43.6 
6 103 512 5 
7 77 666 8.6 
8 51 307 6 
9 0 1741 NA 
10 0 614 NA 
 
Since the relapse of early stage breast cancer is prevalent in this country (Saxena et al. 
2012), blood samples from patients with stage IA–IIIC cancer were obtained 
subsequently to evaluate the ability to detect cancer in the early onset. 53 samples 
were obtained from 32 patients (with no clinically measureable tumor) after surgery 
(see Appendix Table A1.4). 43.4% of all samples generated clusters, an observation 
more prevalent in patients with pathological involvement of 4 or more lymph nodes 
(9/16 (56%)) compared with those with 0–3 lymph nodes (14/37 (38%); p=0.214). 
The metastasis to lymph nodes has been shown to predict prognosis and survival of 
patients (Trojani et al. 1987). Hence, it will be interesting to expand this study to 
obtain more statistically significant results.  
 
Attempts to correlate cluster formation from cultured CTCs with time since surgery 
suggest that 10/20 (50%) of the samples taken shortly after surgery, but before 
adjuvant chemotherapy, formed clusters. For samples taken shortly after 3-6 months 
of adjuvant chemotherapy, cluster formation reduced to just 26% (6/23) but this 
rebounded to 70% (7/10) (p=0.049) for samples obtained 1 year post-adjuvant 
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chemotherapy. This suggests a potential risk of relapse in patients after chemotherapy. 
Among these ten samples (taken shortly after surgery but before adjuvant 
chemotherapy), cluster formation occurred in 2/4 (50%) of patients with pT1N0M0 
disease as compared to 5/6 (83%) patients with higher pathological stage of the 




5.3 Chapter Summary 
173 blood samples of 10 ml each from a total of 60 patients with clinically 
measurable tumors were screened for this study. Overall cluster formation frequency 
was 66.5% (n=173). Putative CK+ CTCs could also be detected in cultured samples 
with initial negligible amount of CK+ CTCs. Cluster formation was reduced in 
samples of later treatment time points, which supports the possibility of monitoring 
CTC cluster formation as an early predictor of treatment response. Correlations 
between cluster formation and the respective demographic details (e.g. lymph node 
involvement) were inconclusive due to the low sample size. 
 
For larger sample sets, verification was done with a two-way analysis of variance 
(ANOVA) (Finak et al.) for the two independent variables (culture positivity and 
patient survival status). 95% confidence intervals were determined. Patients providing 
samples that led to clusters experienced a mean survival period of 9.8 months (95% 
confidence interval (CI), 5.9-13.7), while patients who provided samples that did not 
lead to clusters had a longer mean survival period of 16.6 months (95% CI, 10.4-22.8; 
log rank p-value, 0.087). A Kaplan–Meier survival analysis was performed on the 14 
samples obtained at post-treatment time points (Table 5.2). Graphical representation 
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of the data confirmed that cluster formation correlated with shorter overall survival in 
patients (Figure 5.1). Multivariate analysis of covariance (MANCOVA) for 
continuous independent variables requires large sample sizes and was not utilized in 
this study. 
 
Samples taken from patients shortly after 3-6 months of adjuvant chemotherapy with 
early stage cancer demonstrated a reduction in cluster formation to 26% (6/23) but 
rebounded to 70% (7/10) (p=0.049) for samples obtained 1 year post-adjuvant 
chemotherapy. This suggests a potential risk of relapse in patients after chemotherapy. 
Cluster formation also occurred in a higher proportion (50%, n= 4) of patients with 
pT1N0M0 disease as compared to (83%, n=6) patients with higher pathological stage 
of the disease (p=0.260), which reflects the correlation between the cluster formation 
with disease stage. 
 
Although the results were not statistically significant (due to small sample size), these 






Chapter 6: Conclusions and Future Work 
6.1 Conclusions  
Cancer metastasis often leads to mortality, and CTCs isolated from liquid biopsies 
may serve to illuminate our understanding of mechanisms underlying the spread of 
cancer. Evolving techniques for CTC culture could overcome limitations imposed by 
low sample sizes, thus presenting an unprecedented opportunity to carry out a wider 
range of downstream analysis that can eventually translate into utility for clinical or 
biological aspects.  
 
The current study describes a novel method for the in vitro expansion of CTCs from 
patients with early stage, locally advanced or metastatic breast cancers. RBC-lysed 
blood samples were seeded into non-coated dishes patterned with tapered microwells 
(Figures 2.2) and maintained under hypoxic conditions. Within each microwell, cell 
clusters were observed for the positive samples by Day 14 of culture (Figure 3.7). 
These cultures could be harvested for characterization (Figure 3.9) or passage into 3D 
gel or non-adherent substrates for further proliferation into spheroids (Figure 4.9). 
 
Resultant clusters cultured were heterogeneous in diameter and composition, 
comprising Small putative CTCs (≤25 µm; high N/C ratio; CD45-) and larger blood 
cells (>25 µm; low N/C ratio; CD68+ or CD56+). The proportion of proliferating 
cells (Ki67+) and putative CTC counts (CK+) peaked in most samples at Day 14 of 
culture (Figure 3.4). A proportion of Small cells were detected with copy number 
increase in common breast cancer genes (attributing to ~44% of all subtypes) (Davies 
et al. 2002, Magbanua et al. 2012). Cultured CTCs also vary in terms of EMT status 
(Figures 4.4, 4.6), with a portion shifting towards the mesenchymal subtype under 
hypoxia and microwell conditions. This shift in EMT phenotype is likely to be 
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triggered by hypoxia, which induces EMT via up-regulation of HIF1-Figure 4.10). 
 
Blood cells were known to be present as part of the tumor stoma, and play a role in 
promoting tumor growth (Cortez-Retamozo, 2012 #272). In these cultures, some 
residual blood cells, mainly macrophages or NK cells, were indeed detected as 
minority sub-populations (Figures 3.13-3.17). Although a correlation of blood cells 
with patient outcome was not established at this point of time, it is possible that the 
blood cells could serve as an alternative prognostic factor due to their link to 
inflammation and tumor progression, as reported in previous reports (Finak et al. 2008, 
Gajewski et al. 2013). The blood cells could have also acted as ‘nursing’ cells to 
provide the microenvironment (e.g. cytokine secretion) required to trigger the initial 
CTC proliferation.  
 
Few techniques have reported the enrichment of viable CTCs. Previous culture 
methods focus on promoting proliferation via growth factor supplements and depend 
on spontaneous immortalization to yield robust cell lines (Table 1.3) (He et al. 2007, 
Gao et al. 2014, Yu et al. 2014) (He et al. 2007, Gao et al. 2014, Yu et al. 2014) (He et 
al. 2007, Gao et al. 2014, Yu et al. 2014) (He et al. 2007, Gao et al. 2014, Yu et al. 
2014) (He et al. 2007, Gao et al. 2014, Yu et al. 2014) (He et al. 2007, Gao et al. 2014, 
Yu et al. 2014) (He et al. 2007, Gao et al. 2014, Yu et al. 2014) . These methods are 
relatively costly, and unreliable for clinical evaluation due to their low culture 
efficiency. The development of a novel and sensitive enrichment technique is 
imperative for complete downstream profiling and utility of CTCs. Recent methods 
for the expansion of CTCs have been reported (Table 1.3); however these methods 
still exhibit low efficiency and often require generation of cell lines before utility can 
be achieved. The culture protocol described in this study allowed the characterization 
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of putative primary CTCs after 14 days in culture. Cluster formation correlated 
negatively with patient survival, suggesting its clinical relevance in cancer prognosis 
(Figure 5.2).  
 
 
In this study, the proposed CTC culture method is unique in terms of the 
combinational use of tapered microwells and hypoxia, allowing consistent and rapid 
phenotyping (cluster or no cluster) after 2 weeks in culture. Tapered microwells 
provided a topography which shields cells from fluid shear forces, concentrating 
cellular secretions (which may provide a biochemical niche) and prevent accidental 
disturbance to cells during handling. The shape of the wells (unlike flat microwells) 
promotes cell clustering, further providing resemblance to its microenvironment niche. 
Minimal starting material (petri dishes, 2.5 ml blood sample per 60 mm dish) provides 
a cost effective method of CTC expansion and enrichment (with removal of most 
blood cells). Overall, absence of external factors, which may manipulate cells 
chemically and genetically, reduces the phenotypic changes incurred from in vitro 
maintenance of primary cells.  
 
The short-term nature of this assay favors rapid phenotyping of cultures, enabling 
analysis of serial samples at real-time. Further simplification of the protocol will 
render the assay relevant to clinicians, who can monitor patient response with ease. It 
is possible that cluster size may also correlate with patient prognosis, and this 
parameter will be explored in future studies with a larger sample cohort. 
Characterization of primary cells in a short-term culture is also more advantageous 
than using cell lines, since prolonged culture and passaging often introduce dramatic 
changes in the cells’ epigenetics and gene expression (Lacroix and Leclercq 2004, van 
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Staveren et al. 2009). 
  
The culture assay led to two interesting findings. Firstly, CSC-like cells 
(CD44+/CD24- cells or Rex1+ cells) were detected in the cultures (Figures 4.7-4.8), 
and some cells were likely to be highly invasive (Figure 4.11). Secondly, cluster 
formation was reduced when a patient underwent certain drug regimens, which 
suggested the potential of this assay to reflect treatment efficacy (Figure 5.2). In 
addition, samples obtained from patients with early-stage cancer also led to clusters at 
a higher frequency than existing techniques for early stage cancer detection, thus 
hinting at the potential as a diagnostic technique for predicting relapse (see Appendix 
Table 1.4).  
 
In summary, the CTC culture assay provides a unique and unbiased opportunity to 
expand and enrich rare cancer cells associated with unique parameters (e.g. stemness, 
tumorigenicity, resistance) of the metastatic cascade.  
 
6.2 Future Work 
Moving forward, the assay is currently in the process of evaluation with a larger 
breast sample cohort, as well as samples from other cancer types (e.g. non-small cell 
lung cancer, prostate, spinal and head and neck cancer), so as to validate clinical 
utility and flexibility of the protocol for use in other cancer types. Experiments from 
these trials are still ongoing and hence not mentioned in this study. It is anticipated 
that the use of the CTC culture assay will be focused on short-term evaluation 
purposes, as the current phenotypic changes in CTCs under prolonged culture in vitro 
have yet to be profiled. 
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6.2.1 Bench to bedside applications 
Extensive research on CTCs has now fully demonstrated its independent prognostic 
relevance on patient survival in metastatic breast cancers (Bidard et al. 2014). Past 
attempts to alter treatment strategies to improve patient prognosis had been 
unsuccessful (Smerage et al. 2014), thus heightening the pressing need to develop 
novel therapeutic strategies.  
 
EMT and CSCs are now explored to more clearly define their involvement in cancer 
progression and metastasis, as well as in the case of drug resistance and relapses after 
treatment (Tan et al. 2014). Components of EMT and CSC formation process may be 
investigated for use as novel drug targets. The next application of the CTC culture 
assay is to promote personalized treatment, via monitoring clinical treatment efficacy 
and to carry out drug screening of the CTC clusters obtained from respective patients 
in vitro. Future studies can be aimed to establish multivariate correlations of cluster or 
spheroid formation with cancer stage and treatment time-points. Finally, cultures can 
also be profiled to identify key EMT signatures via transcriptomics or genomics, 
which could open doors for the generation of novel diagnostic devices or therapeutic 
targets. 
  
6.2.2 Insights on metastatic cascade 
Our knowledge of the dynamics of CTCs and their colonization pattern in humans is 
still fragmentary (Pantel and Alix-Panabieres 2007). To facilitate understanding of 
these mechanisms, spheroids obtained from this study may be stained with 
fluorescence dyes and injected into humanized murine mouse models or zebrafish 
models of metastasis for real-time monitoring of their interaction with epithelial or 
blood cells, and transit (persist/becomes trapped or extravasate) in blood vessels. 
 131 
Alternatively, the cultures can also be seeded into disease-on-a-chip devices for the 
investigation of intravasation or extravasation processes in vitro (Aref et al. 2013). 
 
6.2.3 CTC profiling  
It is now widely accepted that CTCs exhibit strong heterogeneity including different 
morphologies and distinct genomic alterations. Differences are also noted in terms of 
epigenetics and proteomics. However, due to challenges for culturing CTCs, there are 
currently only a few studies concerning point mutations in cultured CTCs. Of which, 
these studies either report the presence of heterogeneity (Zhang et al. 2013, Gao et al. 
2014) and/or low frequency (Yu et al. 2014) of the mutations detected.  
 
A preliminary screen with three of the cultured samples using the Cytoscan HD 
analysis revealed a list of major genome-wide alterations (data not shown). Plans are 
currently being made to increase the number of samples and improve the signal versus 
noise ratio by lowering DNA contamination (removal of residual blood cells via 
negative selection with FACS). High resolution sequencing will also be attempted to 
detect single nucleotide polymorphism (SNP) markers, so that samples with 
contaminating (and usually degraded) DNA may also be processed.  
 
Clearly there is an urgent need to further improve phenotyping and genotyping of 
CTCs in relation to prognosis and adaptive treatment. In addition CTCs can also be 
used to evaluate their physical properties such as measurement of membrane elasticity 
using micropipette aspiration or AFM techniques. These additional studies can 
provide further understanding on how CTCs can evade arrest in capillaries, persist in 
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Table A1.1 Clinicopathological characteristics of breast cancer patients with refractory metastatic disease under the CTB clinical trial. C 
= Chinese; M = Malay; I = Indian; O = Others; IDC = invasive ductal carcinoma; ER = oestrogen receptor; PR = progesterone receptor; FAC = 
5-fluouracil/ doxorubicin/cyclophosphamide; Post-Sutent pre-AC are considered as ≤3 weeks after treatment; pre-surgery were considered as 3-5 
















treatment                    
C        44 IDC                                      2 IV       PPN      
LN, small 
liver met                      







C        44 IDC                                      2 IV       PPN      
LN, small 
liver met                      
Docetaxel                                     
Radiological 
response after 2 






treatment                    
C        64 IDC                                      2 IV       NNP      
LN, small 
lung, brain                    











breast        
Vinorelbine and Afatinib                                     
Radiological stable 
disease after 2






treatment                    
I        48 
IDC with 
lobular 
features                
2 IV       PPN      
LN, small 
lung, bone, 
brain              







I        48 
IDC with 
lobular 
features                
2 IV       PPN      
LN, small 
lung, bone, 
brain              
Capecitabine                                                  
Radiologically 
stable disease after 






treatment                    








C        50 IDC                                      2 IV       PPN      Bone, liver                              Fulvestrant                                         
Radiologically 
progressive disease 






treatment                    
C        53 
Metaplastic 
SCC                          
3 IV       NPN      LN, lung                                 
Vinorelbine and 
Capecitabine                                     








C        53 
Metaplastic 
SCC                          
3 IV       NPN      LN, lung                                 
Vinorelbine and 
Capecitabine                                     
Radiologically 
progressive disease 







M        71 IDC 3 IV       PPP      
LN, lung, 
bone                           





treatment                    





bone   












bone   
Fulvestrant                                              
Radiologically 
progressive disease 






treatment                    




invasion              





treatment                    
M        40 IDC                                      3 IV       PPN      
LN, lung, 
bone                           





treatment                    
C        54 IDC                                      3 IV       NNN      Bone                                     
Radiotherapy, 5 
fluorouracil, doxorubicin, 
cyclophosphamide                                            







C        54 IDC                                      3 IV       NNN      Bone                                     
Radiotherapy, 5 
fluorouracil, doxorubicin, 
cyclophosphamide                                                                                    
No documented 







treatment                    





treatment                    
C        57 IDC 3 IV       NNN      LN, lung 
PI3K inhibitor/Placebo + 
Paclitaxel        







C        57 IDC 3 IV       NNN      LN, lung 
PI3K inhibitor/Placebo + 
Paclitaxel        
No documented 
progression within 3 
months 
Y 
21 CTB 3 weeks C        44 IDC                                      3 IV       NNN      LN, lung                                 Gemcitabine+Carboplatin                                     Radiological N 
 157 
 
015  post 
treatment 
response after 2 







C        41 IDC                                      2 IV       PPN      
Bone, 
breast                             
Capecitabine                                                  
Radiologically 
progressive disease 








O        35 IDC                                      . IV       PPN      
Pleura, 
peritoneum, 
small bone          
Letrozole                                                
Radiologically 
stable disease after 






treatment                    








Gemcitabine+Carboplatin                                     
Radiological 










































treatment                    
O        38 IDC 3 IV       PPN      
Lung, bone, 
liver 
Eribulin   Y 
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Table A1.2 Clinicopathological characteristics of breast cancer patients under the PCL clinical trial. C = Chinese; M = Malay; I = Indian; 
O = Others; IDC = invasive ductal carcinoma; ER = oestrogen receptor; PR = progesterone receptor; P: Positive. N: Negative. Post-Sutent pre-
AC are considered as ≤3 weeks after treatment; pre-surgery were considered as 3-5 weeks after treatment; post-surgery were considered as >5 












surgery                      









surgery                         




Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
3 
PCL0









differentiation          
3 IIIB     NPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
4 
PCL0
30   
Pre-
surgery                      




differentiation           
3 IIIB     NPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
5 
PCL0
30   
Post-
surgery 




differentiation           
3 IIIB     NPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
6 
PCL0
31   
Pre-
treatment                    
C        55 IDC                                      2 IIIIA    PPP      
Newly 
diagnosed  









C        55 IDC                                      2 IIIIA    PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
8 
PCL0





C        55 IDC                                      2 IIIA     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            N
9 
PCL0





C        55 IDC                                      2 IIIA     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            N
10 
PCL0
31   
Pre-
surgery                      
C        55 IDC                                      2 IIIA     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            N
11 
PCL0
31   
Post-
surgery 
C        55 IDC                                      2 IIIA     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            N
12 
PCL0
32   
Pre-
treatment                    
M        51 IDC                                      3 IIIB     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
13 
PCL0





M        51 IDC                                      3 IIIB     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
14 
PCL0





M        51 IDC                                      3 IIIB     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
15 
PCL0





M        51 IDC                                      3 IIIB     PPP      
Newly 
diagnosed  




32   
Pre-
surgery                      
M        51 IDC                                      3 IIIB     PPP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            N
17 
PCL0
32   
Post-
surgery 
M        51 IDC                                      3 IIIB     PPP      
Newly 
diagnosed  





treatment                    
C        38 ILC 2 IIA      PPP      
Newly 
diagnosed  








C        38 ILC 2 IIA      PPP      
Newly 
diagnosed  








C        38 ILC 2 IIA      PPP      
Newly 
diagnosed  








C        38 ILC 2 IIA      PPP      
Newly 
diagnosed  





surgery                      
C        38 ILC 2 IIA      PPP      
Newly 
diagnosed  






C        38 ILC 2 IIA      PPP      
Newly 
diagnosed  





treatment                    
C        61 IDC 3 IIIA     NNP      
Newly 
diagnosed  








C        61 IDC 3 IIIA     NNP      
Newly 
diagnosed  











C        61 IDC 3 IIIA     NNP      
Newly 
diagnosed  








C        61 IDC 3 IIIA     NNP      
Newly 
diagnosed  





surgery                      
C        61 IDC 3 IIIA     NNP      
Newly 
diagnosed  
Paclitaxel+carboplatin+lapatinib                         no pCR                                            Y
 1 
Table A1.3 Clinicopathological characteristics of newly diagnosed breast cancer patients from P2A/P2B (doxorubicin/cyclophosphamide 
(AC) with or without Sunitinib) clinical trial.  
C = Chinese; M = Malay; I = Indian; O = Others; IDC = invasive ductal carcinoma; ER = oestrogen; PR = progesterone; FAC = 5-fluouracil/ 
doxorubicin/cyclophosphamide; Post-Sunitinib pre-AC are considered as ≤3 weeks after treatment; pre-surgery and post-surgery are considered 
as >5 weeks after treatment. Y = samples with clusters (positive). N = samples without clusters (negative). 
Sample  Patient ID 
Time-
point 












C        64 IDC                                      3 IIIB     NNN                                               AC                                                       no pCR                                                   Y
2 2 P2A14    
Pre-
treatment                    
C        53 IDC                                      1 IIIA     PPN                                               AC                                                       Y 
3 3 P2A15    
Post 
surgery                         
C        47 
invasive 
micropapillary 
ca               
2 IIIA     PPN                                               AC                                                       
no pCR; chest 
wall recurrence 
while on 
adjuvant RT       
N 





C        47 
IDC with 
micropapillary 
features         
3 IIIB     PPN                                               AC                                                       no pCR                                                   Y





C        47 
IDC with 
micropapillary 
features         
3 IIIB     PPN                                               AC                                                       no pCR                                           Y





C        47 
IDC with 
micropapillary 
features         
3 IIIB     PPN                                               AC                                                       no pCR                                           Y





C        47 
IDC with 
micropapillary 
features         
3 IIIB     PPN                                               AC                                                       no pCR                                           Y
 2 
8 5 P2A17    
Pre-
treatment                    
C        60 IDC                                      3 IIB      PPN                                               AC                                                       Y 





C        60 IDC                                      3 IIB      PPN                                               AC                                                       no pCR                                           Y





C        60 IDC                                      3 IIB      PPN                                               AC                                                       no pCR                                           Y





C        60 IDC                                      3 IIB      PPN                                               AC                                                       no pCR                                           Y





C        60 IDC                                      3 IIB      PPN                                               AC                                                       no pCR                                           N
13 6 P2A18    
Pre-
treatment                    
O        47 IDC                                      3 IIB      NPN                                               AC                                                       Y 





O        47 IDC                                      3 IIB      NPN                                               AC                                                       no pCR                                           Y





O        47 IDC                                      3 IIB      NPN                                               AC                                                       no pCR                                           N
16 6 P2A18    
Post 
surgery                         
O        47 IDC                                      3 IIB      NPN                                               AC                                                       no pCR                                           N
17 7 P2A19    
Pre-
treatment                    
O        46 ILC                                      . IIA      PNN                                               AC                                                       N 




O        46 ILC                                      . IIA      PNN                                               AC                                                       no surgery yet                                 N
 3 
treatment 





O        46 ILC                                      . IIA      PNN                                               AC                                                       no surgery yet                                 N





O        46 ILC                                      . IIA      PNN                                               AC                                                       no surgery yet                                 N 





O        46 ILC                                      . IIA      PNN                                               AC                                                       no surgery yet                                 N





O        46 ILC                                      . IIA      PNN                                               AC                                                       no surgery yet                                 Y
23 7 P2A19 
Post-
surgery 
O        48 IDC                                      4 IIB      NPN        AC                                                       no pCR                                           N
24 8 P2A20    
Pre-
treatment                    
M        45 IDC                                      3 IV       NNN      Bone AC                                                       Y 





M        46 IDC                                      3 IV       NNN      Bone AC                                                       Y 





M        47 IDC                                      3 IV       NNN      Bone AC                                                       N 





M        48 IDC                                      3 IV       NNN      Bone AC                                                       N 
 4 
28 8 P2A20    
Post-
surgery 
M        48 IDC                                      3 IV       NNN      Bone AC                                                       N 
29 9 P2A21    
Pre-
treatment                    
C        38 IDC                                      . IIB      PPN                                               AC                                                       Y 





C        38 IDC                                      . IIB      PPN                                               AC                                                       no surgery yet                                 Y





C        38 IDC                                      . IIB      PPN                                               AC                                                       no surgery yet                                 N





C        38 IDC                                      . IIB      PPN                                               AC                                                       no surgery yet                                 N





C        38 IDC                                      . IIB      PPN                                               AC                                                       no surgery yet                                 N
34 10 P2A22    
Pre-
treatment                    
C        68 IDC                                      2 IIIB     PPN                                               AC                                                       Y 





C        68 IDC                                      2 IIIB     PPN                                               AC                                                       no surgery yet                                 Y





C        68 IDC                                      2 IIIB     PPN                                               AC                                                       no surgery yet                                 Y
37 11 P2A23    
Pre-
treatment                    
C        35 IDC                                      3 IIA      NNN                                               AC                                                       Y 




C        35 IDC                                      3 IIA      NNN                                               AC                                                       no surgery yet                                 Y
 5 
treatment 





C        35 IDC                                      3 IIA      NNN                                               AC                                                       no surgery yet                                 N
40 12 P2A24 
Post-
surgery 
C        33   2 IIB      NPP                                          AC                                                       no surgery yet                                 N
41 13 P2A25 
Pre-
treatment                    
C        46 IDC 2 IIA      NPP                                          AC                                                       no surgery yet                                 Y





C        46 IDC 2 IIA      NPP                                          AC                                                       no surgery yet                                 Y





C        46 IDC 2 IIA      NPP                                          AC                                                       no surgery yet                                 Y





C        46 IDC 2 IIA      NPP                                          AC                                                       no surgery yet                                 Y





C        46 IDC 2 IIA      NPP   AC                                                       no surgery yet                                 Y
46 14 P2A26 
Pre-
treatment 
I        56 IDC 1 IV       NPP                                          AC                                                       no surgery yet                                 Y 





I        56 IDC 1 IV       NPP                                          AC                                                       no surgery yet                                 Y
 6 





I        56 IDC 1 IV       NPP                                          AC                                                       no surgery yet                                 Y 





I        56 IDC 1 IV       NPP                                          AC                                                       no surgery yet                                 Y





I        56 IDC 1 IV       NPP   AC                                                       no surgery yet                                 N
51 14 P2A26 
Post-
surgery 
I        56 IDC 1 IV       NPP   AC                                                       N 
52 15 P2A27 
Pre-
treatment 
C        61 IDC 3 IIB      NPP                                          AC                                                       no surgery yet                                 Y





C        61 IDC 3 IIB      NPP                                          AC                                                       no surgery yet                                 Y





C        61 IDC 3 IIB      NPP                                          AC                                                       no surgery yet                                 Y





C        61 IDC 3 IIB      NPP                                          AC                                                       no surgery yet                                 Y
56 16 P2B08    
Pre-
treatment                    
C        37 IDC                                      3 IIIA     PPN        AC+Sunitinib                                             Y





C        37 IDC                                      3 IIIA     PPN                                               AC+Sunitinib                                             no pCR                              Y
 7 
58 17 P2B09    
Pre-
treatment                    
M        57 IDC                                      3 IIIA     NNN        AC+Sunitinib                                             Y
59 17 P2B09    
Post 
Sutent 
Preuten              
M        57 IDC                                      3 IIIA     NNN                                               AC+Sunitinib                                             no pCR                              Y
60 18 P2B10    
Pre-
treatment                    
C        50 IDC                                      3 IIIB     PPN                                               AC+Sunitinib                                             Y
61 18 P2B10    
Post 
Sutent 
Pre AC               
C        50 IDC                                      3 IIIB     PPN                                               AC+Sunitinib                                             no pCR                              Y





C        50 IDC                                      3 IIIB     PPN                                               AC+Sunitinib                                             no pCR                              Y





C        50 IDC                                      3 IIIB     PPN                                               AC+Sunitinib                                             no pCR                              N
64 19 P2B11    
Pre-
treatment                    
C        45 IDC                                      3 IIA      NNN                                               AC+Sunitinib                                             Y
65 19 P2B11    
Post 
Sutent 
Pre AC               
C        45 IDC                                      3 IIA      NNN                                               AC+Sunitinib                                             pCR                           Y





C        45 IDC                                      3 IIA      NNN                                               AC+Sunitinib                                             pCR                           N





C        45 IDC                                      3 IIA      NNN                                               AC+Sunitinib                                             pCR                           N
68 20 P2B12    
Pre-
treatment                    
C        54 IDC                                      2 IV       NNN      
LN, lung, 
pleura                         
AC+Sunitinib                                             Y
 8 
69 20 P2B12    
Post 
Sutent 
Pre AC               
C        54 IDC                                      2 IV       NNN      
LN, lung, 
pleura                         
AC+Sunitinib                                             no surgery                        Y





C        54 IDC                                      2 IV       NNN      
LN, lung, 
pleura                         
AC+Sunitinib                                             no surgery                        N





C        54 IDC                                      2 IV       NNN      
LN, lungs, 
pleura                        
AC+Sunitinib                                             no surgery                        N
72 21 P2B13    
Pre-
treatment                    
C        46 IDC                                      2 IIB      PPN                                               AC+Sunitinib                                             Y
73 21 P2B13    
Post 
Sutent 
Pre AC               
C        46 IDC                                      2 IIB      PPN                                               AC+Sunitinib                                             no surgery                        Y





C        46 IDC                                      2 IIB      PPN                                               AC+Sunitinib                                             no surgery                        Y





C        46 IDC                                      2 IIB      PPN                                               AC+Sunitinib                                             no surgery                        Y





C        46 IDC                                      2 IIB      PPN                                               AC+Sunitinib                                             no surgery                                 Y





C        46 IDC                                      2 IIB      PPN                                               AC+Sunitinib                                             no surgery                        Y
78 22 P2B14    
Pre-
treatment                    
I        41 IDC                                      3 IIIA     NPN                                               AC+Sunitinib                                             Y
 9 
79 22 P2B14    
Post 
Sutent 
Pre AC               
I        41 IDC                                      3 IIIA     NPN                                               AC+Sunitinib                                             no pCR                              Y





I        41 IDC                                      3 IIIA     NPN                                               AC+Sunitinib                                             no pCR                                                 Y





I        41 IDC                                      3 IIIA     NPN                                               AC+Sunitinib                                             no pCR                                                   Y





I        41 IDC                                      3 IIIA     NPN                                               AC+Sunitinib                                             no pCR                              Y





I        41 IDC                                      3 IIIA     NPN                                               AC+Sunitinib                                             no pCR                              Y
84 23 P2B15    
Pre-
treatment                    
C        45 IDC                                      3 IIIC     NNN                                               AC+Sunitinib                                             Y
85 23 P2B15    
Post 
Sutent 
Pre AC               
C        45 IDC                                      3 IIIC     NNN                                               AC+Sunitinib                                             no pCR      Y





C        45 IDC                                      3 IIIC     NNN                                               AC+Sunitinib                                             no pCR Y





C        45 IDC                                      3 IIIC     NNN                                               AC+Sunitinib                                             
no pCR; 
surgery mixed
IDC/metaplastic                    
Y
88 24 P2B16    
Pre-
treatment                    
O        49 
Mixed 
IDC/ILC                            
2 IIB      PPN                                               AC+Sunitinib                                             Y
 10 
89 24 P2B16    
Post 
Sutent 
Pre AC               
O        49 
Mixed 
IDC/ILC                            
2 IIB      PPN                                               AC+Sunitinib                                             no pCR                                                   Y





O        49 
Mixed 
IDC/ILC                            
2 IIB      PPN                                               AC+Sunitinib                                             no pCR                                                   Y





O        49 
Mixed 
IDC/ILC                            
2 IIB      PPN                                               AC+Sunitinib                                             no pCR                              Y





O        49 
Mixed 
IDC/ILC                            
2 IIB      PPN                                               AC+Sunitinib                                             no pCR                              N
93 24 P2B16    
Post-
surgery 
O        49 
Mixed 
IDC/ILC                            
2 IIB      PPN                                               AC+Sunitinib                                             no pCR                              N





C        48 IDC 3 IIIA     NNN                                               AC+Sunitinib                                             no pCR N





C        48 IDC 3 IIIA     NNN        AC+Sunitinib                                             no pCR N
96 26 P2B19    
Pre-
treatment                    
M        37 IDC                                      1 IIA      PPN                                               AC+Sunitinib                                             no pCR Y
97 26 P2B19    
Post 
Sutent 
Pre AC               
M        37 IDC                                      1 IIA      PPN                                               AC+Sunitinib                                             no surgery yet                          Y





M        37 IDC                                      1 IIA      PPN                                               AC+Sunitinib                                             no surgery yet                          Y
 11 





M        37 IDC                                      1 IIA      PPN                                               AC+Sunitinib                                             no surgery yet                          Y
100 27 P2B21 
Pre-
treatment                    
M        48 IDC 3 IIB      PPP                                          AC+Sunitinib                                             no pCR Y
101 27 P2B21 
Post 
Sutent 
Pre AC               
M        48 IDC 3 IIB      PPP                                          AC+Sunitinib                                             no pCR N
102 27 P2B21 
Post-
surgery 
M        48 IDC 3 IIB      PPP                                          AC+Sunitinib                                             no pCR N





I        54 IDC 3 IIA      NNN                                               AC+Sunitinib                                             no pCR Y





M        44 IDC 3 IIIA     PPP                                          AC+Sunitinib                                             no pCR N





M        44 IDC 3 IIIA     PPP                                          AC+Sunitinib                                             no pCR N





M        44 IDC 3 IIIA     PPP                                          AC+Sunitinib                                             no pCR N
107 29 P2B23 
Post-
surgery 
M        44 IDC 3 IIIA     PPP                                          AC+Sunitinib                                             no pCR N
108 30 P2B24 
Pre-
treatment 
C        47 IDC 3 IIB      PPN                                               AC+Sunitinib                                             no surgery yet                          N
109 30 P2B24 
Post 
Sutent 
Pre AC               









C        47 IDC 3 IIB      PPN                                               AC+Sunitinib                                             no surgery yet                          N





C        47 IDC 3 IIB      PPN                                               AC+Sunitinib                                             no surgery yet                          N





C        47 IDC 3 IIB      PPN                                               AC+Sunitinib                                             no surgery yet                          N





C        47 IDC 3 IIB      PPN        AC+Sunitinib                                             no surgery yet                          N
114 30 P2B24 
Post-
surgery 
C        47 IDC 3 IIB      PPN        AC+Sunitinib                                             N
115 31 P2B25 
Pre-
treatment 
M        57 
invasive 
carcinoma 
3 IIIB     PPN                                               AC+Sunitinib                                             defaulted N
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Table A1.4 Clinicopathological characteristics of breast cancer patients under the CES (early-stage cancer, no metastatic sites) clinical 
trial. C = Chinese; M = Malay; I = Indian; O = Others; IDC = invasive ductal carcinoma; ER = oestrogen receptor; PR = progesterone receptor; 
FAC = 5-fluouracil/ doxorubicin/cyclophosphamide; TCH = post adjuvant Herceptin+Docetaxel+Carboplatin; FEC = Fluorouracil, Epirubicin, 
and Cyclophosphamide; Post-Sutent pre-AC are considered as ≤3 weeks after treatment; pre-surgery were considered as 3-5 weeks after 
treatment; post-surgery were considered as >5 weeks after surgery. Y = samples with clusters (positive). N = samples without clusters (negative). 




ID Time point Race Age Histology Grade TNM 
ER/PR/ 
HER2 





C      
  
59 
IDC                 
                     
1 T1N1M0 PPN      FAC Y 
2   
CES 0
01  
Post adjuvant chemotherapy 
C      
  
59 
IDC                 
                     
1 T1N1M0 PPN      FAC Y 
3   
CES 0
01  
1 year post FAC 
C      
  
59 
IDC                 
                     





C      
  
67 
IDC                 
                     
2 T2N0M0 PPN      FAC Y 




C      
  
67 
IDC                 
                     





C      
  
60 
IDC                 
                     
3 T3N3M0 PPN      AC Y 
7   
CES 0
03  
1 year post taxol 
C      
  
60 
IDC                 
                     





C      
  
57 
IDC                 
                     
3 T1N0M0 PPP      AC Y 
 14 
9   
CES 0
04  
1 year after surgery and adjuv
ant chemotherapy 
C      
  
57 
IDC                 
                     





C      
  
50 
IDC                 
                     
2 T1N0M0 PPN      AC N 
11   
CES0
05  
1 year post AC 
C      
  
50 
IDC                 
                     




Post adjuvant AC 
M     
   
49 IDC 3 T3N1M0 PPN      AC N  
13   
CES0
06 
1 year after surgery and adjuv
ant chemotherapy 
M     
   
49 IDC 3 T3N1M0 PPN      AC N  




M     
   




Post adjuvant paclitaxel 
C      
  
44 IDC 3 
cT2N1M0, 
ypT1N0M0 
PPP      
AC (neoadjuva
nt) followed by




16   
CES0
08 
1 year after surgery and adjuv
ant chemotherapy 
C      
  
44 IDC 3 
cT2N1M0, 
ypT1N0M0 
PPP      
AC (neoadjuva
nt) followed by








C      
  









C      
  





O      
  






C      
  















C      
  








C      
  








C      
  




25     Post paclitaxel 
C      
  







Post adjuvant paclitaxel 
C      
  




PPN      
Neoadjuvant A







Post adjuvant paclitaxel 
C      
  




28   
CES0
18 
1 year after surgery and adjuv
ant chemotherapy 
C      
  







Post adjuvant docetaxel  
O      
  








O      
  




31   
CES0
21 
1 year after surgery and adjuv
ant chemotherapy 
O      
  







1 year after surgery and adjuv
ant chemotherapy 
C      
  
46 IDC 3 T2N0M0 NNN      
AC followed b






Post-surgery I        35 IDC 3 T2N1M0 PPN      
AC followed b






O      
  
44 IDC 2 T2N0M0 PPN      
FEC followed 
by docetaxel  
N  
35   
CES0
24 
Post adjuvant chemotherapy 
O      
  
44 IDC 2 T2N0M0 PPN      
FEC followed 






M     
   




37   
CES0
25 
1 year after surgery and adjuv
ant chemotherapy 
M     
   








M     
   








M     
   








M     
   








M     
   








C      
  













C      
  
46 IDC 3 T1N0M0 NNN      TC N 




C      
  





C      
  




46   
CES0
30 
Post adjuvant chemotherapy 
C      
  










C      
  
41 IDC 2 T1N1M0 PPP      TC N 




C      
  





M     
   








C      
  








C      
  
38 IDC 3 
cT2N0M0, 
ypT0N0M0 





C      
  
35 IDC 3 T1N1M0 PPN      
Neoadjuvant A








C      
  
44 IDC 2 T1N0M0 PPN      TC N 
